

1 **Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update**
2 **2020**

3 **Authors:**

4 David J. Gladstone¹ (Chair, First Author), M. Patrice Lindsay² (Corresponding Author), James
5 Douketis³, Eric E Smith⁴, Dar Dowlatshahi⁵, Theodore Wein⁶, Aline Bourgoin⁷, Jafna Cox⁸, John
6 B. Falconer⁹, Brett R. Graham¹⁰, Marilyn Labrie¹¹, Lena McDonald¹², Jennifer Mandzia¹³,
7 Daniel Ngui¹⁴, Paul Pageau¹⁵, Amanda Rodgerson¹⁶, William Semchuk¹⁷, Tammy Tebbutt¹⁸,
8 Carmen Tuchak¹⁹, Stephen van Gaal²⁰, Karina Villaluna²¹, Norine Foley²², Shelagh Coutts⁴,
9 Anita Mountain²³, Gord Gubitz²⁴, Jacob A Udell²⁵, Rebecca McGuff², and Alexandre Y. Poppe²⁶
10 (Co-Chair, Senior Author); on Behalf of the Canadian Stroke Best Practice Recommendations
11 Advisory Committee, in collaboration with the Canadian Stroke Consortium.

12 **Affiliations:**

13 1. Division of Neurology, Department of Medicine, and Regional Stroke Centre, Hurvitz Brain
14 Sciences Program, Sunnybrook Health Sciences Centre and Sunnybrook Research Institute,
15 Toronto, Canada; 2. Heart and Stroke Foundation of Canada, Toronto, Canada; 3. Department of
16 Medicine, McMaster University, Hamilton, Canada; 4. University of Calgary, Cumming School
17 of Medicine, Department of Clinical Neurosciences, Calgary, Canada; 5. University of Ottawa,
18 Department of Neurology, Ottawa, Canada; 6. Stroke Prevention Clinic, McGill University
19 Health Centre, Montreal, Canada; 7. Stroke Prevention Clinic, Champlain Regional Stroke
20 Network, Ottawa, Canada; 8. Departments of Medicine and of Community Health and
21 Epidemiology, Dalhousie University, Halifax, Canada; 9. Division of Neurology, Faculty of
22 Medicine, University of British Columbia, Kelowna, Canada; 10. Faculty of Medicine,
23 Department of Neurology, University of Saskatchewan, Saskatoon, Canada; 11. Faculty of
24 Medicine (Neurology), Laval University, Quebec City, Canada; 12. Heart Health Clinic, St.
25 Martha's Regional Hospital, Antigonish, Canada; 13. Department of Clinical Neurological
26 Sciences, Western University, London, Canada; 14. Dept of Family Medicine, University of
27 British Columbia, Vancouver, Canada; 15. The Ottawa Hospital, Department of Emergency

28 Medicine, Ottawa, Canada; 16. Provincial Rehabilitation Unit, Queen Elizabeth Hospital,
29 Charlottetown, Canada; 17. College of Pharmacy, University of Saskatchewan; Regina, Canada;
30 18. District Stroke Centre, Waterloo Wellington, Kitchener, Canada; 19. Division of Physical
31 Medicine and Rehabilitation, University of Alberta, Edmonton, Canada; 20. Division of
32 Neurology, Faculty of Medicine, University of British Columbia, Vancouver, Canada; 21.
33 Vancouver Stroke Program, Vancouver, Canada; 22. WorkHORSE Consulting Inc, London,
34 Canada; 23. Queen Elizabeth II Health Sciences Centre, Nova Scotia Rehabilitation Centre Site,
35 Halifax, Canada; 24. Queen Elizabeth II Health Sciences Centre, Stroke Program, Halifax,
36 Canada; 25. Division of Cardiology, Department of Medicine, Faculty of Medicine, University
37 of Toronto, Toronto, Canada; 26. Department of Neurosciences, Centre hospitalier de
38 l'Université de Montréal (CHUM), Montréal, Canada.

39 **Corresponding Author:**

40 Dr. M. Patrice Lindsay, RN, PhD, FWSO
41 Senior Editor, Canadian Stroke Best Practice Recommendations
42 Director, Health Systems Change,
43 Heart and Stroke Foundation, Canada
44 PH: +1-647-528-4361 Email: patrice.lindsay@heartandstroke.ca

45 **Contributions:**

46 David J Gladstone (First author) and Alexandre Y Poppe (Senior Author) are co-chairs of the
47 *Secondary Prevention of Stroke* expert writing group and lead authors contributing to all aspects
48 of the development, evidence and data analysis, writing, editing and final approval of this
49 manuscript; M. Patrice Lindsay is corresponding author, senior editor of the Canadian Stroke
50 Best Practice Recommendations and of this manuscript, involved in all aspects of scientific
51 literature review, writing group deliberations, external review process, manuscript preparation
52 and a writer of supplementary documentation. Aline Bourgoin, Jafna Cox, James Douketis, John
53 B. Falconer, Brett R. Graham, Marilyn Labrie, Lena McDonald, Jennifer Mandzia, Daniel Ngui,
54 Paul Pageau, Amanda Rodgerson, William Semchuk, Tammy Tebbutt, Carmen Tuchak, Jacob
55 Udell, Stephen van Gaal, Karina Villaluna are all members of Secondary Prevention of Stroke
56 expert writing group and contributed by reviewing, analyzing and discussing the evidence and
57 collectively finalizing the wording of all included recommendations. Norine Foley conducted the
58 evidence searches and completed the evidence tables and evidence summaries supporting this
59 guideline update and contributed to writing of this manuscript. Dar Dowlathahi, Theodore
60 Wein, Eric E. Smith, Anita Mountain and Gord Gubitz and are senior leaders of the stroke best
61 practices advisory committee and provided inputs throughout development of the
62 recommendations, and participated in development, preparation and editing of this manuscript.
63 Shelagh Coutts led a subgroup focused on updates to section one recommendations for triage.
64 Rebecca McGuff provided inputs to this manuscript and is responsible for development of
65 knowledge translation resources.
66

67 Total Manuscript Word Count: 14,385 (excluding tables, figures, abstract, acknowledgements,
68 declaration of conflicts of interest, funding and references)

69 Abstract Word Count: 250 words

70 Tables: 0 Figures: 0

71 **Supplemental Material File (Separate Document as an online supplement)**

72 Supplemental File One contains 4 Appendices:

- 73 1. Definitions
- 74 2. Laboratory Investigations
- 75 3. Table: Summary of Perioperative Management of Anti thrombotic agents
- 76 4. Core elements of Secondary Stroke Prevention care

77

78 Supplemental File Two:

- 79 1. Final Secondary Prevention Manuscript translated into French

80

81 **Abstract**

82 The 2020 update of the Canadian Stroke Best Practice Recommendations (CSBPR) for the
83 *Secondary Prevention of Stroke* includes current evidence-based recommendations and expert
84 opinions intended for use by clinicians across a broad range of settings. They provide guidance
85 for the prevention of ischemic stroke recurrence through the identification and management of
86 modifiable vascular risk factors. Recommendations address triage, diagnostic testing, lifestyle
87 behaviors, vaping, hypertension, hyperlipidemia, diabetes, atrial fibrillation, other cardiac
88 conditions, antiplatelet and anticoagulant therapies, and carotid and vertebral artery disease. This
89 update of the previous 2017 guideline contains several new or revised recommendations.
90 Recommendations regarding triage and initial assessment of acute TIA and minor stroke have
91 been simplified, and selected aspects of the etiological stroke workup are revised. Updated
92 treatment recommendations based on new evidence have been made for dual antiplatelet therapy
93 for TIA and minor stroke; anticoagulant therapy for atrial fibrillation; embolic strokes of
94 undetermined source; LDL lowering; hypertriglyceridemia; diabetes treatment; and PFO
95 management. A new section has been added to provide practical guidance regarding temporary
96 interruption of antithrombotic therapy for surgical procedures. Cancer-associated ischemic stroke
97 is addressed. A section on virtual care delivery of secondary stroke prevention services in
98 included to highlight a shifting paradigm of care delivery made more urgent by the global
99 pandemic. Additionally, where appropriate, sex differences as they pertain to treatments have
100 been addressed. The CSBPR include supporting materials such as implementation resources to
101 facilitate the adoption of evidence into practice and performance measures to enable monitoring
102 of uptake and effectiveness of recommendations.

103 **Keywords:** stroke, transient ischemic attack, guidelines, secondary prevention, risk assessment,
104 management

105 **Introduction**

106 Optimizing stroke prevention is a major public health priority. Stroke remains a leading cause of
107 adult neurological disability (both physical and cognitive), dementia, and death globally. The
108 seventh update of the Canadian Stroke Best Practice Recommendations (CSBPR) *Secondary*
109 *Prevention of Stroke* guidelines includes a summary of current evidence-based recommendations
110 for healthcare professionals. They focus on reducing the risk of recurrent stroke following an
111 index ischemic stroke or TIA and are applicable to patients managed across a variety of care
112 settings. They emphasize a coordinated and organized approach to assessment and aggressive
113 risk factor management. The core elements of integrated and effective secondary stroke
114 prevention services are included in the Supplemental material, Appendix Four. Patient
115 management aims to identify treatable risk factors, apply evidence-based treatment interventions
116 to minimize risk, provide patient education and shared decision-making, and encourage patient
117 adherence and persistence with treatment recommendations.

118 These recommendations have been developed in collaboration with the Canadian Stroke
119 Consortium. We collaborate with the Canadian Cardiovascular Society, Thrombosis Canada,
120 Diabetes Canada, and Hypertension Canada to ensure alignment of recommendations wherever
121 possible. Those guidelines should be consulted for additional detail and information beyond the
122 scope of the CSBPR. *The Canadian Stroke Best Practice Recommendations (CSBPR) Secondary*
123 *Prevention of Stroke 2020 Seventh Edition module supersedes all recommendations contained in*
124 *the CSBPR Secondary Prevention of Stroke 2017 Sixth Edition module.*

125 **Guideline Development Methodology**

126 The Canadian Stroke Best Practice Recommendations development and update process follows a
127 rigorous framework^{1,2} and addresses all criteria defined within the AGREE Trust model.³ The
128 methodology for development and updates to the CSBPR has previously published^{4,5} and
129 detailed methodology can be found on our Canadian Stroke Best Practices website at
130 www.strokebestpractices.ca. A broad interdisciplinary group of experts was convened and
131 participated in reviewing, drafting, and revising all recommendation statements, and a panel of
132 people with lived experience participated in a parallel review process.⁶ Evidence levels were
133 assigned based on the quality of available evidence and expert opinion. These guidelines have
134 undergone extensive internal and objective external review and consensus was achieved for all

135 content. For additional methodology and information on these recommendations, including
136 Rationale, System Implications, Performance Measures, Knowledge Translation and
137 Implementation Tools and an extended Summary of the Evidence, please visit
138 <https://www.strokebestpractices.ca/recommendations/secondary-prevention-of-stroke>.

139 **Secondary Prevention of Stroke Recommendations**

140 **Section 1: Triage and Initial Diagnostic Evaluation of transient ischemic attack and non-** 141 **disabling stroke**

142 An acute TIA or minor stroke is a medical emergency. Initial management aims to establish an
143 accurate diagnosis, determine the likely etiology, and institute secondary prevention therapy as
144 quickly as possible. Patients with acute TIA or minor stroke are at risk of recurrent stroke both in
145 the short-term (particularly within the first week)⁷ and long-term.⁸ Our triage recommendations
146 have been simplified to focus on patients presenting within the first 48 hours of a suspected new
147 acute TIA or stroke as they are at highest risk of early recurrent stroke. For such patients,
148 immediate assessment is recommended, with imaging of both brain (head CT or MRI) and
149 vessels (ideally with a CT angiogram from aortic arch to vertex) on an urgent basis.⁹

150 An embolic stroke or TIA can be the first manifestation of previously unrecognized atrial
151 fibrillation. We recommend a tiered approach to searching for atrial fibrillation in patients with a
152 new acute embolic ischemic stroke or TIA.¹⁰ The goal of post-stroke ECG monitoring is to detect
153 high-burden atrial fibrillation for which anticoagulation would likely be beneficial. However,
154 ECG monitoring often reveals brief subclinical paroxysmal atrial fibrillation, and it remains
155 unclear what amount of device-detected atrial fibrillation warrants anticoagulation. Trials
156 underway are evaluating this question. The effect of post-stroke prolonged ECG monitoring on
157 hard clinical outcomes (i.e. recurrent stroke) remains to be determined and is the subject of
158 ongoing research (FIND-AF2 trial, NCT04371055).

159 Echocardiography can be a valuable tool in the etiological assessment and risk stratification of
160 patients with stroke and TIA. However, it can be overutilized and we recommend responsible use
161 of this resource. Thus, the recommendations emphasize that echocardiography is not required for
162 all stroke patients but should be considered for those with an embolic ischemic stroke or TIA of
163 undetermined source (ESUS) or when a cardioembolic etiology or paradoxical embolism is

164 suspected.

165 We have recommended against extensive thrombophilia testing for hereditary hypercoagulable
166 disorders in the routine investigation of adults with arterial ischemic stroke events. Such testing
167 is often overused in practice and should be limited to selected patients such as those with
168 unexplained cerebral venous thrombosis or PFO-related paradoxical embolism.

169 An important lesson of the COVID-19 pandemic has been how essential remote or virtual
170 contact with patients and families is to providing safe and timely care for stroke patients. In
171 particular, care for patients living in rural or remote communities or patients for whom mobility
172 and transport to clinic or hospital are prohibitive, can be improved via virtual care. Home blood
173 pressure monitoring is encouraged in accordance with CHEP guidelines.¹¹ Home delivery of
174 ECG patch monitors that can be self-applied by patients is a welcome option in regions where it
175 is available. Virtual care interventions can be effective for blood pressure lowering,
176 improvements in diet, increased physical activity, drug adherence, and satisfaction with access to
177 care,¹² reduced HgbA1c, smoking cessation,¹³ and reduced risk of cardiovascular events.¹⁴

Section One Recommendations 2020

1.0 Patients with acute stroke or transient ischemic attack who present to an ambulatory setting (such as primary care) or a hospital should undergo clinical evaluation by a healthcare professional with expertise in stroke care to determine risk for recurrent stroke and initiate appropriate and timely investigations and management strategies.

1.1 HIGH Risk for Recurrent Stroke (Symptom onset within last 48 Hours)

- i. Individuals presenting within 48 hours of symptoms consistent with a new acute stroke or transient ischemic attack event (especially transient focal motor or speech symptoms, or persistent stroke symptoms) are **at the highest risk for recurrent stroke** and should be immediately sent to an emergency department (refer to Clinical Consideration 1.1.3) with capacity for stroke care (including on-site brain imaging, and ideally access to acute stroke treatments) [Evidence Level B].
- ii. Urgent brain imaging (CT or MRI) with concurrent neurovascular imaging (e.g., CT angiography [CTA]) should be completed as soon as possible and before discharge

from the Emergency Department [Evidence Level B].

- iii. Patients presenting after 48 hours from the onset of an acute stroke or transient ischemic attack event should receive a comprehensive clinical evaluation and investigations as soon as possible by a healthcare professional with stroke expertise [Evidence Level B].

Section 1.1 Clinical Considerations:

1. Referral to a healthcare professional with expertise in stroke care should be considered for patients with a suspected uncommon cause of stroke, including for young stroke patients (e.g., < 45 years);¹⁵ family history of young-onset stroke; suspected cerebral vasculitis or other intracranial vasculopathy; or suspected hereditary or acquired thrombophilia.
2. Patients presenting with symptoms of vertebrobasilar ischemia may present with fluctuating brainstem/cerebellar type symptoms (e.g., diplopia, dysarthria, dysphagia, non-positional vertigo, ataxia; rarely as isolated symptoms) over a longer time course (i.e., more than 48 hours) and can be mistaken for stroke mimics; however, they also require urgent assessment, neurovascular imaging and management as these types of strokes can have a high morbidity. Consultation with a healthcare professional with expertise in stroke care is strongly encouraged.
3. Setting: In some regions, urgent/rapid transient ischemic attack clinics are available that have rapid access to diagnostic services, and they may be considered as appropriate referral options for transient ischemic attack and minor stroke patients where available and accessible.

1.2 Brain and Vascular Imaging

- i. Brain imaging (CT or MRI) and non-invasive vascular imaging (CTA or MR Angiogram (MRA) from aortic arch to vertex) should be completed as soon as possible following acute stroke or transient ischemic attack [Evidence Level B].
 - a. CTA of head and neck (from aortic arch to vertex), which can be performed at

the time of initial brain CT, is recommended as an ideal way to assess both the extracranial and intracranial circulation [Evidence Level B]. *Note: Some facilities may not have CTA readily available; the timing and type of vascular imaging will need to be based on available resources and local practice protocols.*

- b. Neurovascular imaging is recommended to identify patients with significant symptomatic extracranial carotid artery stenosis (i.e., 50-99% stenosis), which should trigger an urgent referral for potential carotid revascularization [Evidence Level A].
- c. CTA is the first-line vascular imaging test for stroke/ transient ischemic attack patients. MRA and carotid ultrasound (for extracranial vascular imaging) are reasonable alternatives to CTA as first-line tests for assessment of carotid vessels if CTA is not possible, and selection should be based on availability and patient characteristics [Evidence Level C].

Section 1.2 Clinical Considerations:

1. Brain MRI is superior to a head CT scan in terms of diagnostic sensitivity for identifying small ischemic lesions in patients presenting clinically with a transient ischemic attack or minor stroke event, and can provide additional information for guiding diagnosis, prognosis, and treatment decision-making. Decisions regarding MRI scanning should be based on MRI access, availability and timing of appointments. For maximal diagnostic yield, MRI should be completed as soon as possible after the symptomatic event, ideally within 7 days of symptom onset. MRI is particularly useful in lower risk patients with transient symptoms in whom the presence of ischemia would change their management.
2. Common scenarios where urgent brain MRI can be valuable include:
 - a. Normal CT head despite symptoms persisting > 24 hours (if DWI-MRI is negative, cerebral ischemia is unlikely).

- b. Suspected brainstem or cerebellar ischemia (CT head is insensitive for detecting strokes in the posterior fossa due to bone artifact).
- c. Focal transient symptoms that are clinically atypical for ischemia.

1.3 Blood Work

- i. The following laboratory investigations should be routinely considered for patients with a transient ischemic attack or minor ischemic stroke as part of the initial evaluation:
 - a. **Initial bloodwork:** hematology (complete blood count), electrolytes, coagulation (aPTT, INR), renal function (creatinine, estimated glomerular filtration rate), random glucose, ALT [Evidence Level C]. *Refer to Appendix Two for full list of recommended lab tests.*
 - b. **Additional** laboratory tests may be completed during patient encounter or as an outpatient, including a lipid profile (fasting or non-fasting); and screening for diabetes with either a glycated hemoglobin (HbA1c), fasting glucose or 75 g oral glucose tolerance test [Evidence Level C].
 - c. **(NEW FOR 2020):** If giant cell arteritis is suspected (e.g., retinal ischemia or headache), ESR and CRP should be measured [Evidence Level C].
- ii. **(NEW FOR 2020):** Extensive thrombophilia testing for hereditary hypercoagulable disorders is not recommended for routine investigation of a patient with arterial ischemic stroke and should be limited to selected situations (for example, but not limited to, unexplained cerebral venous thrombosis; PFO-related paradoxical embolism) [Evidence Level C].
 - a. If a hypercoagulable state is suspected, consider consultation with a healthcare professional with Hematology or Thrombosis expertise [Evidence Level C].

1.4 Cardiac Studies

1.4 A Detection of Atrial Fibrillation

- i. Patients with suspected ischemic stroke or transient ischemic attack should have a 12-lead ECG to assess for atrial fibrillation, concurrent myocardial infarction, or structural

heart disease (e.g., left ventricular hypertrophy) as potential causes or risk factors of stroke [Evidence Level B].

- ii. For patients being investigated for an acute embolic ischemic stroke or transient ischemic attack, ECG monitoring for 24 hours or more is recommended as part of the initial stroke work-up to detect paroxysmal atrial fibrillation in patients who would be potential candidates for anticoagulant therapy [Evidence Level A].
- iii. For patients being investigated for an embolic ischemic stroke or transient ischemic attack of undetermined source whose initial short-term ECG monitoring does not reveal atrial fibrillation but a cardioembolic mechanism is suspected, continuous ECG monitoring for at least 2 weeks is recommended to improve detection of paroxysmal atrial fibrillation in selected patients aged ≥ 55 years who are not already receiving anticoagulant therapy but who would be potential candidates for anticoagulant therapy [Evidence Level A].
- iv. **(NEW FOR 2020):** For patients aged >65 years with ischemic stroke or transient ischemic attack, pulse palpation or heart auscultation or ECG rhythm strip is recommended to screen for undiagnosed atrial fibrillation [Evidence Level B].

1.4 B Echocardiography

- i. Echocardiography should be considered for patients with an embolic ischemic stroke or transient ischemic attack of undetermined source or when a cardioembolic etiology or paradoxical embolism is suspected [Evidence Level C]. Routine echocardiography is not required for all stroke patients. [Evidence Level C].
- ii. **(NEW FOR 2020):** For patients aged 60 years or younger who are being investigated for an embolic ischemic stroke or transient ischemic attack of undetermined source, echocardiography with saline bubble study is recommended for detection of a possible PFO if it may change patient management (i.e., in patients who would be potential candidates for PFO closure or anticoagulant therapy if a PFO were detected) [Evidence Level B].
 - a. Contrast-enhanced (agitated saline) transesophageal echocardiography or

transcranial Doppler has greater sensitivity than transthoracic echocardiography for detection of right-to-left cardiac and extra-cardiac shunts [Evidence Level B].

1.5 Functional Assessment:

- i. Patients with stroke should be assessed for neurological impairments and functional limitations (e.g., cognitive evaluation, screening for depression, screening for dysphagia, screening of fitness to drive, need for potential rehabilitation therapy, and assistance with activities of daily living) [Evidence Level B].
- ii. Patients found to have neurological impairments and functional limitations should be considered for referral to the appropriate rehabilitation specialist for in-depth assessment and management [Evidence Level B].

1.6 Virtual Care for Secondary Stroke Prevention (New 2020)

- i. Secondary stroke prevention services should establish processes and technology to increase and ensure access to services through virtual care delivery mechanisms for patients who do not require in-person visits, and especially patients living in rural and remote settings without local access to healthcare professionals with stroke expertise [Evidence Level C].
 - a. Clinicians should follow established/validated criteria to determine the best modality for each patient at each encounter based on the purpose and goals for each visit [Evidence Level C].
 - b. Shared decision-making should also take into account patient values, preferences, health goals, medical complexity, social determinants of health, and health needs [Evidence Level C].

Section 1.6 Clinical Considerations:

1. Consulting sites and individual clinicians should have triage protocols and local intake criteria in place to ensure patients referred for their services are seen in a timely

manner, especially high-risk patients as described in Section 1.1 of this module.

2. The use of virtual care for stroke prevention should include decision tools to identify patients who require in-person visits and those who can reasonably be managed through virtual care, and a scheduling mechanism for virtual visits that support a collaborative team approach to care where appropriate and feasible.
3. A contingency plan should be established to have patients seen in person in a timely way should the need arise following a virtual care encounter.
4. Virtual care-enabled evaluations of patients for secondary stroke prevention should be modeled on the topics defined in the Post Stroke Checklist and core elements of stroke prevention care.
5. Validated approaches to virtual neurological exams should be followed.
6. Barriers to access, equity and utilization should be considered and work-around solutions implemented.
7. Ensure processes in place for booking follow-up tests, referrals and other consultations following a virtual care visit.
8. Ensure appropriate documentation and communication to other team members who may also be involved in care remotely.
9. Encourage patients and their families to acquire home blood pressure monitors where appropriate and provide education or reliable resources on proper use. Mechanisms should be in place for follow-up and management of BP for patients using home BP devices, by either primary care providers or SPS.
10. For timely investigations, consider use of prolonged cardiac monitors, if available, that can be sent to patient's homes and self-applied, then returned by mail.
11. Data collection and quality improvement mechanisms should be in place to monitor efficiency, effectiveness and quality of virtual care encounters.

179 **Section 2: Lifestyle Behaviours and Risk Factor Management**

180 A healthy lifestyle, which includes a Mediterranean or Dietary Approaches to Stop Hypertension
181 (DASH) diet, exercise, weight control, reduction and avoidance of alcohol and tobacco, reduces
182 the risk of an initial stroke and the risk of a subsequent stroke for patients with a prior history of
183 stroke. Although individually, these habits can reduce the risk of stroke, their impact is greater
184 when combined. Even greater impacts can be achieved with population level interventions for
185 physical activity include investments in health promoting infrastructure (e.g., sidewalks, walking
186 paths, bike lanes). At the core of these of interventions is a focus on making the healthy choice
187 the easy choice.

Section 2 Recommendations 2020

2.1 Risk Factor Assessment:

- i. Persons at risk of stroke and patients who have had a stroke or transient ischemic attack should be assessed for vascular disease risk factors, lifestyle management issues (diet, sodium intake, exercise, weight, alcohol intake, smoking), as well as use of oral contraceptives or hormone replacement therapy [Evidence Level B].
- ii. Persons at risk of stroke or transient ischemic attack and their family members should receive individualized information and counselling about possible strategies to modify their lifestyle and vascular risk factors [Evidence Level B].
- iii. Referrals to appropriate specialists should be made to support and manage specific vascular risk factors and lifestyle behaviours and choices where required [Evidence Level B].

2.2 Healthy Balanced Diet

- i. Counsel and educate individuals with transient ischemic attack or stroke to follow a healthy eating pattern and balanced diet [Evidence Level B] or refer to a Registered Dietitian where available [Evidence Level C].
- ii. Counsel and educate individuals with transient ischemic attack or stroke to follow a Mediterranean-type or DASH (Dietary Approach to Stop Hypertension) diet, which is high in vegetables, fruit, whole grains, fish, nuts and olive oil and low in red meat

[Evidence Level B].

iii. Counselling may include:

- a. consuming a variety of natural, whole, and minimally processed foods at each meal [Evidence Level B].
- b. consuming fewer highly processed foods, which include refined foods, confectionaries, sugary drinks, processed meats and meat alternatives, and pre-prepared foods [Evidence Level B].
- c. consuming a diet high in vegetables and fruit; encourage patients to choose fresh or frozen unsweetened fruit, or fruit canned in water without added sugars and low in sodium; fresh or frozen vegetables without added sauces, or canned vegetables with no added salt [Evidence Level B].
- d. consuming lower fat and lower sugar dairy products and unsweetened fortified soy beverages [Evidence Level B].
- e. shift to consuming more protein from plant-based sources (legumes, nuts and seeds) and other protein options which are lower in saturated fats such as fish, poultry, and lean meats [Evidence Level B].
- f. consuming high fibre choices such as whole grains, beans, and legumes instead of processed or refined grains such as white bread and pasta [Evidence Level B].
- g. consuming water as the drink of choice for hydration. Sugary drinks (such as energy drinks, fruit drinks, juice, soft drinks, and flavored coffees) add calories and have little to no nutritional value and should be discouraged [Evidence Level A].
- h. consuming foods low in sodium [Evidence Level B].

Section 2.2 Clinical Consideration

1. Counsel and educate individuals regarding healthy eating patterns that focus on whole, natural, minimally processed foods, instead of specific nutrients such as dietary cholesterol.

2.3 Sodium Intake

- i. To prevent hypertension and to reduce blood pressure in patients with hypertension, counsel and educate individuals with transient ischemic attack or stroke to reduce sodium intake to a goal of no more than 2000 mg (5 g table salt or 87 mmol sodium, equal to less than one teaspoon) per day [Evidence Level A].

Section 2.3 Clinical Consideration

- i. Achieving a sodium intake of < 2000 mg may be very difficult for the general population and average daily intake among people in Canada is 2760 mg. Encourage a gradual decrease in foods that are high in sodium which will allow taste buds and behaviour to adapt appropriately.

2.4 Physical Activity

- i. Counsel and educate individuals with transient ischemic attack or stroke to reduce sedentary behaviors and sedentary time, and to work towards increased activity goals as tolerated [Evidence Level B].
- ii. Most individuals post stroke who are medically stable should start a regular exercise program [Evidence Level B].
- iii. Counsel and educate individuals with transient ischemic attack or stroke to participate in aerobic exercise 4 to 7 days per week, to accumulate at least 150 minutes per week in episodes of 10 minutes or more, in addition to routine activities of daily living [Evidence Level B].
- iv. Initiation of aerobic training should be considered after a stroke or transient ischemic attack once the patient is medically stable. To ensure continuity of appropriate interventions, patients should be reassessed at transition points along the continuum of care based on changing neuromotor and cardiopulmonary capacities to participate in aerobic training [Evidence Level B].

Section 2.4 Clinical considerations

1. Aerobic exercise intensity should be individualized. Factors to consider include

functional limitation, co-existing medical problems such as cardiac disease, need for an exercise stress test with electrocardiogram, and planned exercise intensity (i.e., light, moderate, or vigorous).

2. Screening and supervision of adults with comorbid disease such as cardiac disease which places them at higher risk of medical complications should be considered.
3. Supervision by a healthcare professional (such as a physiotherapist) at exercise initiation should be considered in individuals with stroke at risk of falls or injury.

2.5 Weight Management

- i. Counsel and educate individuals with transient ischemic attack or stroke to achieve and maintain a waist circumference of <88 centimeters for women and <102 centimeters for men*, or a body mass index (BMI) of 18.5 to 24.9 kg/m² [Evidence Level B].
*(*Note: these numbers are reflective of current research based mostly on Caucasian patients. Refer to Reference list for waist circumference values for other ethnic groups)*
- ii. Counsel and educate individuals with transient ischemic attack or stroke who are overweight to set healthy weight loss goals and develop individualized plans to achieve goals [Evidence Level B].
- iii. A multi-pronged approach should be used to support sustainable weight loss or weight gain that includes counselling and education, increased physical activity, and behavioural interventions [Evidence Level B].

Section 2.5 Clinical Consideration

1. When discussing weight, consider completion of a comprehensive history that explores root causes of weight gain and avoids stigma and judgment.

2.6 Alcohol Consumption

- i. Counsel and educate individuals with transient ischemic attack or stroke to avoid heavy alcohol use as excessive alcohol intake increases the risk of hypertension, ischemic stroke and intracerebral hemorrhage. [Evidence Level B].
- ii. Counsel and educate individuals with transient ischemic attack or stroke to follow Canada's Low-Risk Alcohol Drinking Guidelines (2018): for women, no more than 10 drinks per week, with no more than 2 drinks per day most days and no more than 3 drinks on any single occasion; for men, no more than 15 drinks per week, with no more than 3 drinks per day most days and no more than 4 drinks on any single occasion [Evidence Level B].

Note: one standard drink is considered to be approximately 44 mL (1.5 oz) of 80 proof (40%) spirits, 355 mL (12 oz) of 5% beer or 148 mL (5 oz) of 12% wine.

2.7 Recreational Drug Use

- i. Individuals with stroke and known recreational drug use that may increase the risk of stroke (such as cocaine, amphetamines) should be counseled to discontinue use [Evidence Level C]; and should be provided with appropriate support and referrals to services and resources for drug addiction and rehabilitation.
- ii. For cannabis, that may be prescribed for medical indications, counsel patients regarding any potential increased risk of stroke to support informed decision-making regarding the use of these agents [Evidence Level B].

Section 2.7 Clinical Consideration

1. At present, there has been some association of smoking cannabis products with possible increased stroke and cardiovascular events. However, there is a lack of high-quality evidence to provide clear guidance. Individual patient factors should be considered.

2.8 Smoking Cessation

Note, the term 'Smoking' in these recommendations refers to tobacco and other inhaled

substances.

- i. In all healthcare settings along the stroke continuum (inpatient, ambulatory, and community), patient smoking status should be identified, assessed, and documented [Evidence Level A].
- ii. Provide unambiguous, non-judgmental, and patient-specific advice regarding the importance of cessation to all smokers [Evidence Level B] and others who reside with the patient.
- iii. Offer assistance with the initiation of a smoking cessation attempt – either directly or through referral to appropriate resources [Evidence Level A].
- iv. A stepwise approach that starts with reduction in smoking and progresses to full cessation is a valid approach [Evidence Level B].
- v. A combination of pharmacotherapy and behavioural therapy should be considered in all smoking cessation programs and interventions [Evidence Level A].
- vi. The three classes of pharmacological agents that should be considered as first-line therapy for smoking cessation are nicotine replacement therapy, varenicline and bupropion [Evidence Level A].
 - a. The choice of appropriate pharmacotherapy should take into account the patient's medical stability, clinical needs, other medical factors, patient preferences and patient's ability to afford the therapy in those cases where it is not covered under a provincial drug formulary [Evidence Level C].
 - b. The initiation of pharmacotherapy for smoking cessation should begin as soon as possible and supported while in hospital for index stroke-related event [Evidence Level C]. Earlier initiation of smoking cessation discussions may be beneficial [Evidence Level C].
- vii. For stroke patients in hospital who are current smokers, protocols should be in place to manage nicotine withdrawal during hospitalization [Evidence Level B].
- viii. Interdisciplinary team members should counsel patients, family members, and caregivers about the harmful effects of exposure to environmental (second – hand)

smoke [Evidence Level B].

- ix. A referral to virtual smoking cessation services, smoking cessation programs, supportive resources and clinics should be considered depending on regional availability to optimize the success of smoking cessation [Evidence Level B]
- x. People who are not ready to quit should be offered a motivational intervention to help enhance their readiness to quit [Evidence Level B].

Section 2.8 Clinical Considerations

Use of E-Cigarettes

1. While some individuals may find vape products helpful in smoking cessation, the evidence base around their population-based effectiveness is not clear.
2. There is some evidence that shows people who use vaping as a mechanism to quit cigarettes may continue to vape even after cessation of cigarette use, in contrast to use of nicotine replacement therapy which has not been found to be continued in an ongoing basis.¹⁶
3. Emerging evidence indicates an association between vaping and elevated blood pressure; the strength of the association is not clear at this time.
4. The most common pattern of use in Canada is dual use of both vape and combustible tobacco products and therefore smoking cessation strategies should include consideration for both methods of nicotine consumption”.
5. Education and counselling should be provided regarding the risks versus benefits of e-cigarettes in people with stroke, including in younger age groups who have experienced stroke.

2.9 Pregnancy, Oral Contraceptives and Hormone Replacement Therapy

- i. Discussions of pregnancy and implications for stroke recurrence should be included as a routine part of post-stroke management for all female stroke survivors of reproductive age [Evidence Level C].

- ii. Contraception should be addressed based upon the patients' fertility and pregnancy plans as well as the stroke mechanism and type [Evidence Level C].
- iii. In cases of ischemic stroke, systemic estrogen-containing contraceptives or hormone replacement therapy that can increase the risk of thrombosis should be carefully considered and, in most cases, should be avoided due to an increased risk of stroke [Evidence Level B].
- iv. Management alternatives, including progesterone-only oral contraceptives, progesterone-only or non-hormonal intrauterine devices, or barrier contraception can be considered in consultation with a provider experienced with contraceptive methods [Evidence Level C].
- v. Estrogen-containing oral contraceptives or hormone replacement therapy should be discouraged or discontinued in female patients with transient ischemic attack or ischemic stroke [Evidence Level B]. Management alternatives should be considered in these patients [Evidence Level C].
- vi. **(NEW for 2020)** Contraceptive management alternatives to estrogen containing hormonal contraceptives should be considered for women with a history of migraine with aura [Evidence Level C], especially if they are also current tobacco smokers [Evidence Level B].¹⁷
- vii. **Hypertensive Disorders of Pregnancy:** Discussion on the use and dose of ASA to reduce the risk of a hypertensive disorder of pregnancy (HDP) should be individualized based upon a woman's risk of HDP (i.e., women with a prior ischemic stroke, prior HDP or other risk factors) and in consultation with obstetrical care providers [Evidence Level C]. *Refer to CSBPR Stroke during Pregnancy recommendations for additional information.*
- viii. **Invitro Fertilization:** For women who have had a cerebral event and are considering invitro fertilization, provide counselling and education about risks of fertility therapy including the potential risk of hyperstimulation, and monitor for complications assuming all other stroke in the young management plans followed and optimized [Evidence Level C].

2.10 Adherence to individual prevention plans

- i. At each healthcare encounter, discuss and document patient adherence to their prescribed secondary prevention treatment plans (pharmacotherapy and lifestyle changes), explore and address non-adherence, and provide counselling and engage in joint goal setting to encourage adherence and persistence with treatment [Evidence Level C].

2.11 Emerging Risk Factors

Influenza infection, vaccination, and stroke risk

- i. Influenza vaccination is recommended as it has been shown to be associated with a decreased risk of stroke or cardiovascular events, particularly in patients with pre-existing cardiovascular risk factors [Evidence Level B].

Air pollution and stroke risk

- i. Counsel individuals regarding long-term exposure to air pollutants, particularly avoiding or minimizing exposure to particulate matter $\leq 2.5 \mu\text{m}$ in diameter, which may be associated with an increased risk of stroke and cardiovascular disease [Evidence Level B].

188 Section 3: Blood pressure and stroke prevention

189 Hypertension is the major modifiable risk factor for stroke. In Canada, systolic hypertension is
190 estimated to account for about 45% of the total stroke burden.¹⁸ While the optimal target blood
191 pressure to prevent a first or recurrent stroke has not been formally established, the current
192 treatment recommendation to attain a blood pressure of consistently lower than 140/90 mm Hg
193 for people who have had an ischemic stroke or transient ischemic attack, can help to reduce
194 recurrent events. Using the results from a subset of 13 randomized controlled trials (RCTs) that
195 included persons with a previous history of stroke, Law et al.¹⁹ reported that blood pressure
196 treatment resulting in a reduction of 10 mm Hg systolic and 5 mm Hg diastolic was associated
197 with a 34% reduced risk of recurrent stroke (RR=0.66, 95% CI 0.56 to 0.79). In the RESPECT
198 trial²⁰ persons with a history of stroke within the previous 30 days to three years who were
199 randomized to a standard treatment group with a target of <140/90 mm Hg or an intensive

200 treatment group with a target of <120/80 mm Hg, did not have a significantly reduced risk of
201 recurrent stroke (HR=0.73, 95% CI 0.49-1.11, p=0.15); however, when these results were
202 incorporated into an updated meta-analysis, the risk was reduced significantly with intensive
203 therapy. The number needed to treat to prevent one recurrent stroke was 67, with an absolute risk
204 reduction of 1.5%.

Section 3 Recommendations 2020

3.0 Blood pressure should be assessed and managed in all persons with stroke or transient ischemic attack [Evidence Level A].

3.1 Blood pressure assessment

- i. All persons at risk of recurrent stroke should have their blood pressure measured routinely [Evidence Level A], no less than once annually and more frequently based on individual clinical circumstances [Evidence Level C].
- ii. Proper standardized techniques should be followed for initial and subsequent blood pressure measurement including office, home, and community testing [Evidence Level B] as outlined by the Hypertension Canada Guidelines.
- iii. Patients found to have an automated office measured resting elevated blood pressure (systolic greater than 135 mm Hg and/or diastolic greater than 85 mm Hg) should undergo thorough assessment for the diagnosis of hypertension [Evidence Level C].
 - a. During an office visit for assessment of hypertension consider taking the average of three blood pressure measurements conducted in accordance with the current Hypertension Canada Guidelines [Evidence Level C]. *Refer to Hypertension Canada Algorithm for Diagnosis of Hypertension, including Home Blood Pressure Monitoring Targets.*
- iv. Patients with refractory hypertension should have comprehensive investigations for secondary causes of hypertension [Evidence Level B].
- v. Patients with hypertension or at risk for hypertension (in pre-hypertension state or other risk factors) should receive aggressive risk factor modification, lifestyle counselling

and lifestyle modification interventions [Evidence Level B].

3.2 Blood pressure management

- i. Strong consideration should be given to the initiation of antihypertensive therapy after the acute phase of a stroke or transient ischemic attack [Evidence Level A].
- ii. For patients **who have had an ischemic stroke or transient ischemic attack**, blood pressure lowering treatment is recommended to achieve a target of consistently lower than 140/90 mm Hg [Evidence Level B]; this includes individuals with chronic kidney disease.
- iii. For patients **who have had a small subcortical stroke (i.e., lacunar stroke)**, aggressive blood pressure lowering treatment is reasonable to achieve a systolic target of consistently lower than 130 mm Hg [Evidence Level B].
- iv. **In patients with intracerebral hemorrhage**, blood pressure should be aggressively monitored, treated, and controlled [Evidence Level A] to sustain a target blood pressure consistently lower than 130/80 mm Hg [Evidence Level B]. *Refer to Canadian Stroke Best Practice Recommendations: Management of Intracerebral Hemorrhage module.*
- v. **In patients with stroke and diabetes**, blood pressure lowering treatment is recommended for the prevention of first or recurrent stroke to attain a target systolic blood pressure consistently lower than 130 mm Hg [Evidence Level C] and a target diastolic blood pressure consistently lower than 80 mm Hg [Evidence Level A].
- vi. Randomized controlled trials have not defined the optimal time to initiate blood pressure lowering therapy after an acute stroke or transient ischemic attack. Blood pressure lowering treatment should be initiated or modified before discharge from hospital [Evidence Level B].
- vii. Treatment with an ACE inhibitor and thiazide/thiazide-like diuretic combination is recommended [Evidence Level A]. Long-acting diuretics may be considered over short-acting [Evidence Level B]. *

viii. The use of an ACE inhibitor combined with an ARB is not recommended [Evidence Level B]. *

ix. Patients who are not started on antihypertensive therapy in acute care should have arrangements made for follow-up with primary care or stroke prevention service for ongoing evaluation and management [Evidence Level C]. *Note: Blood pressure management is the responsibility of all healthcare team members, and initially stroke patients may require frequent monitoring (e.g., monthly) until they achieve target blood pressure levels and optimal therapy has been established.*

*Notes: * For recommendations on specific agents and sequence of agents in blood pressure management for the secondary prevention of ischemic stroke, refer to the current [Hypertension Canada treatment guidelines](#)¹¹*

Section 3 Clinical Considerations

1. **(New for 2020)** For patients with a non-revascularized critical intracranial or extracranial arterial stenosis who are experiencing neurological symptoms attributed to hemodynamic (low flow) cerebral or retinal ischemia (e.g. orthostatic TIAs), it is reasonable to aim for higher than usual blood pressure targets (i.e. permissive hypertension), and avoidance of hypotension, for prevention of hemodynamic stroke; if such patients are asymptomatic, then usual blood pressure targets should be followed in the post-acute phase of stroke.

205 Section 4: Lipid management

206 New evidence supports more aggressive lipid management for secondary stroke prevention. The
207 recommended target LDL cholesterol level has been lowered to <1.8 mmol/L, from previously-
208 recommended targets of LDL <2.0 mmol/L or 50% LDL reduction. If this target cannot be
209 achieved with maximum tolerated statin therapy, ezetimibe or a PCSK9 inhibitor may be added
210 for ischemic stroke patients with atherosclerotic disease. Clinicians are reminded that lipid
211 lowering therapies are not recommended for secondary prevention of intracerebral hemorrhage,

212 or for patients with cardioembolic ischemic stroke (e.g. atrial fibrillation) in the absence of
213 atherosclerotic disease.

214 The Treat Stroke to Target trial studied 2,860 patients with atherosclerotic disease who had an
215 ischemic stroke within the previous 3 months or a TIA within the previous 15 days. Treatment to
216 an LDL cholesterol target < 1.8 mmol/L, as compared to a target of 2.3-2.8 mmol/L, was
217 associated with a lower risk of major cardiovascular events over a median of 3.5 years (8.5% vs.
218 10.9%, HR=0.78, 95% CI 0.61 to 0.98; p=0.04).²¹ About a third of patients in this study required
219 the addition of ezetimibe to their high-dose statin to achieve the more aggressive LDL target.

220 Treatment of hypertriglyceridemia with icosapent ethyl 2 g bid may be considered for patients
221 with ischemic stroke who have established atherosclerotic cardiovascular disease, or diabetes
222 plus additional vascular risk factors, and elevated serum triglycerides (≥ 1.5 mmol/L) despite
223 statin therapy.

Section 4 Recommendations 2020

4.0 Individuals who have had an ischemic stroke or transient ischemic attack should have their serum lipid levels assessed and optimally managed [Evidence level A].

4.1 Lipid Assessment

- i. Lipid levels, including total cholesterol, triglycerides, low-density lipoprotein [LDL] cholesterol, and high-density lipoprotein [HDL] cholesterol, should be measured in patients presenting with ischemic stroke or transient ischemic attack [Evidence Level B].
Refer to Appendix Two for more information on laboratory tests.

4.2 Lipid Management

- i. Individuals with ischemic stroke or transient ischemic attack should be managed with aggressive lifestyle changes to lower lipid levels, including dietary modification and exercise, as part of a comprehensive approach to lower risk of recurrent stroke and other vascular events unless contraindicated [Evidence Level B].

- ii. Statin pharmacotherapy should be prescribed for secondary prevention of stroke in individuals who have had a non-cardioembolic ischemic stroke or transient ischemic attack, [Evidence Level A].
 - a. A target LDL cholesterol level of < 1.8 mmol/L is recommended [Evidence Level B].
- iii. Statin therapy should not be initiated for secondary prevention of intracerebral hemorrhage [Evidence Level C].²²
- iv. **Add-on therapies for LDL-Lowering (NEW 2020):**
 - a. For individuals with ischemic stroke and atherosclerotic cardiovascular disease with an LDL > 1.8 mmol/L in spite of maximal tolerated statin therapy, ezetimibe may be considered for additional LDL lowering [Evidence Level B].
 - b. For individuals with concomitant atherosclerotic cardiovascular disease where target LDL level is not achievable, consider referral to a health professional with expertise in metabolic and lipid management, or stroke expertise for consideration of **adding PCSK9 inhibitor** [Evidence Level A].
- v. **Add-on therapies for hypertriglyceridemia (NEW 2020)** For ischemic stroke patients with established atherosclerotic cardiovascular disease or diabetes plus additional vascular risk factors, who have elevated serum triglyceride levels (≥ 1.5 mmol/L) despite statin therapy, icosapent ethyl 2 g bid may be considered to decrease the risk of vascular events [Level of Evidence B].

4.3 Statin Intolerance (new 2020)

- i. For patients with an intolerance to statins (including persistent myalgias, persistent significant liver enzyme abnormalities or rarely, myopathy or rhabdomyolysis), the indication for statin therapy should be confirmed and in general, systematic evaluation of the contribution of statins to the patient's symptoms should be considered (including temporary statin cessation with observation of symptoms, dose-adjustment, use of alternate agents) [Evidence Level C]

224 **Section 5: Diabetes Management in stroke**

225 In Canada, almost 2.5 million people have type 1 or 2 diabetes.²³ Diabetes is known to increase
226 the risk of ischemic stroke by 227%.²⁴ Although tighter glycaemic control along with other risk
227 factor reduction strategies, can collectively help to reduce stroke risk, on its own, aggressive
228 glycaemic control does not reduce stroke risk.^{25, 26} However, trials of newer antihyperglycaemic
229 agents, including SGLT-2 and GLP-1 receptor agonists, have demonstrated benefit for major
230 cardiovascular outcomes, including stroke.²⁷⁻³¹

Section 5 Recommendations 2020

5.0 Patients with diabetes who have had an ischemic stroke or transient ischemic attack should have their diabetes assessed and optimally managed [Evidence Level A].

5.1 Diabetes Screening and Assessment

- i. Patients with ischemic stroke or transient ischemic attack should be screened for diabetes with either a fasting plasma glucose, or 2-hour plasma glucose, or glycated hemoglobin (A1C), or 75 g oral glucose tolerance test in either an inpatient or outpatient setting [Evidence Level C].
- ii. For patients with diabetes and either ischemic stroke or transient ischemic attack, glycated hemoglobin (A1C) should be considered as part of a comprehensive stroke assessment [Evidence Level B].

5.2 Diabetes Management

- i. Glycaemic targets should be individualized to achieve:
 - a. In general, A1c values should be targeted to $\leq 7.0\%$ in patients with either type 1 or type 2 diabetes (and stroke or transient ischemic attack), as this target provides strong benefits for the prevention of microvascular complications [Evidence Level A].
 - b. To achieve a target of A1c $\leq 7.0\%$, most patients with type 1 or type 2 diabetes

should aim for a fasting plasma glucose or pre-prandial plasma glucose target of 4.0 to 7.0 mmol/L [Evidence Level B].

- c. The 2-hour postprandial plasma glucose target is 5.0 to 10.0 mmol/L [Evidence Level B].
 - d. If A1C targets cannot be achieved with a postprandial target of 5.0 to 10.0 mmol/L, further postprandial blood glucose lowering, to 5.0 to 8.0 mmol/L, should be considered [Evidence Level C].
- ii. **(New 2020)** In patients with stroke and type 2 diabetes in whom glycemic targets are not achieved with standard oral antihyperglycemic medications, an antihyperglycemic agent with demonstrated benefit on major cardiovascular outcomes (for example, SGLT-2 inhibitors or GLP-1 receptor agonists) should be considered [Evidence Level B].

Section 5.2 Clinical Consideration (New 2020):

1. The *Pioglitazone after Ischemic Stroke or Transient Ischemic Attack* trial³² suggested that while there is a benefit of pioglitazone for stroke prevention in patients with positive insulin resistance, it is offset by the increased risk of fractures and bladder cancer. A post-hoc analysis of patients in the trial with prediabetes and good drug adherence suggested a benefit of pioglitazone over placebo with regards to stroke, acute coronary syndrome, stroke/MI/hospitalization for heart failure, and progression to diabetes. The decision to use this agent could be considered based on the specific risk profile for each patient.

231

232 Section 6.0: Antiplatelet therapy for individuals with ischemic stroke or transient ischemic **233 attack**

234 Short-term administration of dual antiplatelet therapy with aspirin and clopidogrel is
235 recommended for secondary stroke prevention, starting within 24 hours for eligible patients with
236 acute non-hemorrhagic high-risk TIA or minor ischemic stroke based on the POINT,³³

237 CHANCE,³⁴ and FASTER³⁵ trials. The optimal duration of dual antiplatelet therapy has been
238 clarified by additional analyses^{36,37} with net benefit of dual antiplatelet therapy over aspirin
239 alone likely confined to the first 21 days post-TIA/stroke (maximal within the first 10 days).
240 Compared with aspirin, the short-term dual antiplatelet therapy protocol prevents 20 more
241 strokes (and causes 2 major bleeds) for every 1000 patients treated. Pharmacogenetic testing can
242 identify patients with clopidogrel resistance, however its clinical implications for stroke
243 prevention practice are unclear at this time.³⁸⁻⁴⁰

244 Another short-term dual antiplatelet treatment option is the combination of daily low-dose
245 aspirin and ticagrelor, a P2Y12 antagonist most often used in coronary artery disease. The
246 THALES trial tested a 30-day course of the aspirin-ticagrelor combination starting within 24
247 hours of a high-risk TIA or minor ischemic stroke.⁴¹ Ticagrelor was administered as a 180 mg
248 loading dose followed by 90 mg twice daily, along with aspirin 75-100 mg daily. This
249 combination reduced the risk of recurrent stroke or death compared with aspirin alone, although
250 the risk of severe bleeding, intracranial bleeding and fatal bleeding were higher in the ticagrelor-
251 aspirin group. Maximum benefit was observed in patients with ipsilateral large vessel
252 atherosclerotic disease.⁴²

253 The defining features of ESUS are an acute brain infarct visualized on neuroimaging (not a
254 subcortical lacune <1.5 cm); absence of proximal atherosclerotic vessel stenosis >50%; no atrial
255 fibrillation or other major-risk cardioembolic source; and no other likely cause for the stroke.⁴³
256 Patients with ESUS have an average annual stroke recurrence risk of approximately 5%. Two
257 trials published since the last edition investigated whether patients with ESUS would benefit
258 more from anticoagulation than aspirin. Neither trial showed found a significant reduction in
259 recurrent stroke risk and therefore anticoagulation is not recommended for patients with ESUS.^{60,}
260⁴⁴ The lack of an overall benefit of anticoagulation likely reflects that ESUS comprises a
261 heterogeneous group of many etiologies, with atherosclerotic or other mechanisms likely
262 predominating over occult atrial fibrillation in the patients enrolled in these trials. The
263 ARCADIA trial (NCT03192215) is testing apixaban vs. aspirin in a subset of ESUS patients who
264 have markers of atrial myopathy.

Section 6 Recommendations 2020

6.1 Acute Antiplatelet Therapy

- i. All patients with acute ischemic stroke or transient ischemic attack not already on an antiplatelet agent should be treated with at least 160 mg of acetylsalicylic acid immediately as a one-time loading dose after brain imaging has excluded intracranial hemorrhage [Evidence Level A].
- ii. For patients with dysphagia, acetylsalicylic acid (80 mg daily) or clopidogrel (75 mg daily) may be administered by enteral tube or acetylsalicylic acid by rectal suppository (325 mg daily) [Evidence Level A]. *Note acetylsalicylic acid should only be administered orally once dysphagia screening has been performed and indicates absence of potential dysphagia.*
- iii. Antiplatelet therapy should be started as soon as possible after brain imaging has excluded hemorrhage, within 24 hours of symptom onset (ideally within 12 hours) [Evidence Level B].
- iv. For patients receiving intravenous thrombolysis therapy, avoid antiplatelet therapy within the first 24 hours; antiplatelet therapy could then be initiated after brain imaging has excluded secondary hemorrhage [Evidence Level B].
- v. For transient ischemic attack or minor ischemic stroke patients who are being discharged from the emergency department, antiplatelet therapy should be started prior to discharge [Evidence Level C].

6.2 Antiplatelet Therapy for Secondary Stroke Prevention

- i. For patients with ischemic stroke or transient ischemic attack, antiplatelet therapy is recommended for long-term secondary stroke prevention to reduce the risk of recurrent stroke and other vascular events unless there is an indication for anticoagulant therapy [Evidence Level A].
- ii. Antiplatelet therapy should be started as soon as possible after brain imaging has excluded hemorrhage, within 24 hours of symptom onset (ideally within 12 hours)

[Evidence Level B].

- iii. For long-term secondary stroke prevention, either acetylsalicylic acid (80 mg – 325 mg daily), or clopidogrel (75 mg daily), or combined acetylsalicylic acid and extended-release dipyridamole (25mg/200 mg BID), are all appropriate treatment options and selection depends on patient factors or clinical circumstances [Evidence Level A]

6.2.1 Short-Term Dual Antiplatelet Therapy for Secondary Stroke Prevention

- iv. For patients with an acute high-risk transient ischemic attack or minor ischemic stroke of non-cardioembolic origin (NIHSS 0-3), who are not at high bleeding risk, dual antiplatelet therapy is recommended with clopidogrel 75 mg daily plus acetylsalicylic acid 81 mg daily for a duration of 21 days after the event, followed by antiplatelet monotherapy thereafter (acetylsalicylic acid or clopidogrel alone) [Evidence Level A].
- v. **(REVISED for 2020):** Dual antiplatelet therapy for longer than the first 21 days following a transient ischemic attack or minor stroke **is not recommended** unless there is a specific indication (e.g., arterial stent; symptomatic intracranial artery stenosis), due to an increased risk of bleeding without clear benefit beyond 21 days [Evidence Level B]. Patients should be counseled that dual antiplatelet therapy with acetylsalicylic acid and clopidogrel should continue for only 21 days, followed by antiplatelet monotherapy to be continued indefinitely.
- vi. A single loading dose of clopidogrel (either 300 mg (CHANCE trial) or 600 mg (POINT trial)) and acetylsalicylic acid (160 mg - 325 mg) should be administered at the start of treatment [Evidence Level A].
- vii. **(NEW FOR 2020):** Another reasonable short-term dual antiplatelet treatment option is the combination of daily low-dose acetylsalicylic acid plus ticagrelor (180 mg loading dose, followed by 90 mg bid) for 30 days [Evidence Level B].
- viii. **(NEW FOR 2020):** For patients with a recent stroke or transient ischemic attack due to symptomatic intracranial atherosclerotic stenosis of 70-99%, and a low estimated bleeding risk, the SAMMPRIS protocol should be considered, which includes dual

antiplatelet therapy (acetylsalicylic acid and clopidogrel) for the first 3 months, typically followed by antiplatelet monotherapy thereafter, in addition to intensive lipid-lowering therapy with high-dose statin, blood pressure treatment, and structured lifestyle modification addressing smoking cessation, exercise and diet [Evidence Level B].

6.2.2 Specific Clinical Situations

- ix. **(NEW FOR 2020):** For patients with an embolic stroke of undetermined source, and no known atrial fibrillation, anticoagulant therapy **is not currently recommended** over low-dose acetylsalicylic acid for secondary stroke prevention [Evidence Level A].
Additional trials are ongoing to investigate this issue.

Section 6.2 Clinical Considerations

- i. For patients who experience a stroke while receiving one antiplatelet agent, stroke etiology should be reassessed and addressed, and all other vascular risk factors aggressively managed. Either continuing the current agent or switching to a different antiplatelet agent are reasonable options. At the present time, evidence is lacking to make more specific recommendations.
- ii. **(NEW FOR 2020):** Pharmacogenetic testing can identify patients with clopidogrel resistance, however its clinical implications for stroke prevention treatment are unclear at this time.
- iii. **(NEW FOR 2020):** For carefully selected patients with coronary artery disease or peripheral vascular disease meeting the eligibility criteria of the **COMPASS trial**, including a low estimated bleeding risk and no history of lacunar stroke or hemorrhagic stroke, the combination of rivaroxaban 2.5 mg BID plus daily low-dose acetylsalicylic acid is a reasonable treatment option. It should not be used within the first month after a stroke event.

267 **Section 7: Anticoagulant Therapy for Atrial Fibrillation**

268 Oral anticoagulant therapy is strongly recommended for secondary stroke prevention in patients
269 with atrial fibrillation. Anticoagulation for AF has been associated with a 66% relative risk
270 reduction of recurrent stroke, with an absolute risk reduction of 7.3%.⁴⁵ Direct oral
271 anticoagulants (DOAC) are generally preferred over warfarin for most patients with non-valvular
272 atrial fibrillation (non-valvular is now defined as atrial fibrillation without moderate-severe
273 mitral stenosis or mechanical heart valves).⁴⁶ A recent trial supports the use of rivaroxaban over
274 warfarin for patients with atrial fibrillation and a bioprosthetic mitral valve.⁴⁷

275 Clinicians are reminded to avoid inappropriate under-dosing of DOACs, a practice that is
276 associated with increased stroke risk. For patients with atrial fibrillation and chronic stable
277 coronary artery disease (or >1-year post-PCI or CABG), the addition of an antiplatelet agent to
278 chronic DOAC therapy is not recommended as it increases bleeding risk without providing
279 additional benefit in reducing ischemic events (cardiac or cerebral). The AFIRE trial showed that
280 rivaroxaban alone was as effective as the combination of rivaroxaban and aspirin in this patient
281 population, with a lower incidence of bleeding.⁴⁸

Section 7 Recommendations

7.1 Detection of Atrial Fibrillation following Stroke.

- i. Patients with suspected ischemic stroke or transient ischemic attack should have a 12-lead ECG to assess for atrial fibrillation, myocardial infarction, or structural heart disease (e.g., left ventricular hypertrophy) as potential causes or risk factors of stroke [Evidence Level B].
- ii. For patients being investigated for an acute embolic ischemic stroke or transient ischemic attack, ECG monitoring for 24 hours or more is recommended as part of the initial stroke work-up to detect paroxysmal atrial fibrillation in patients who would be potential candidates for anticoagulant therapy [Evidence Level A].
- iii. For patients being investigated for an embolic ischemic stroke or transient ischemic attack of undetermined source *whose initial short-term ECG monitoring does not reveal atrial fibrillation* but a cardioembolic mechanism is suspected, prolonged ECG monitoring for at least 2 weeks is recommended to improve detection of paroxysmal

atrial fibrillation in selected patients aged ≥ 55 years who are not already receiving anticoagulant therapy but would be potential anticoagulant candidates [Evidence Level A].

- iv. **(NEW FOR 2020):** For patients aged >65 years with ischemic stroke or transient ischemic attack, routine pulse palpation is recommended to screen for undiagnosed atrial fibrillation [Evidence Level C].

7.2 Secondary Stroke Prevention in Patients with Atrial Fibrillation

- i. Patients with ischemic stroke or transient ischemic attack and atrial fibrillation should receive oral anticoagulant therapy for secondary stroke prevention [Evidence Level A].
 - a. **(New for 2020):** For patients with an ischemic stroke or transient ischemic attack and atrial fibrillation, oral anticoagulant therapy is strongly recommended [Evidence Level A]. It is recommended over acetylsalicylic acid [Evidence Level A] and dual antiplatelet therapy [Evidence level B].
 - b. For most patients requiring anticoagulants for non-valvular atrial fibrillation, a direct oral anticoagulant (DOAC) such as apixaban, dabigatran, edoxaban, or rivaroxaban should be prescribed in preference over warfarin [Evidence Level A].
 - c. For patients already receiving warfarin with good International Normalized Ratio (INR) control (range 2.0 – 3.0, with time in therapeutic range (TTR) of $>70\%$) and without adverse effects, continuing warfarin, rather than switching to a DOAC, is a reasonable anticoagulant option [Evidence Level B]. Patient preferences should be considered in decision-making [Evidence Level C].
 - d. When selecting an oral anticoagulant, patient specific criteria should be considered [Evidence Level C].
- ii. For patients with acute ischemic stroke and atrial fibrillation who are being started on warfarin, routine use of bridging with heparin is not recommended [Evidence Level B].
 - a. Bridging with antiplatelet therapy (e.g., low-dose acetylsalicylic acid) is

suggested until the patient is anticoagulated within therapeutic range [Evidence Level C].

- iii. For patients with ischemic stroke or transient ischemic attack and atrial fibrillation who are unable to take oral anticoagulant therapy (DOAC or warfarin), acetylsalicylic acid alone is recommended unless also contraindicated [Evidence Level A].
 - a. For patients at high risk of bleeding, dual antiplatelet therapy is not recommended in preference to anticoagulation as the risks of bleeding are comparable, and dual antiplatelet therapy is less effective for stroke prevention [Evidence Level B].
- iv. For ischemic stroke or transient ischemic attack in patients with atrial fibrillation who cannot receive long-term oral anticoagulant therapy, a left atrial appendage occlusion procedure may be considered [Evidence Level B].
- v. For patients with a mechanical heart valve, warfarin is recommended for stroke prevention with careful INR monitoring; direct oral anticoagulants (DOACs) are contraindicated [Evidence Level B]. *Note, patients with bioprosthetic heart valves do not routinely require long-term anticoagulation.*
- vi. **(New for 2020):** For patients with atrial fibrillation who experience ischemic stroke or transient ischemic attack in spite of anticoagulant therapy, we recommend the following: (1) identify and address medication nonadherence; (2) ensure correct DOAC dosing or warfarin INR control; (3) avoid DOACs drug-drug interactions; (4) investigate for and treat other potential stroke etiologies, and (5) promote general vascular risk factor modification [Evidence Level C].

Section 7.2 Clinical Considerations Revised for 2020:

Timing of Initiation of Oral Anticoagulant Therapy following Acute Stroke:

1. The optimal timing to start anticoagulant therapy after an ischemic stroke has not yet been well defined by clinical trial evidence and should be based on individual benefit/risk assessment taking into account the clinical circumstances, stroke severity, infarct size, imaging appearances, risk of hemorrhagic transformation, age,

comorbidities, and estimated stroke recurrence risk.

2. There is a lack of randomized evidence to guide specific timing. According to expert consensus, a general approach to the target timing of initiation of DOAC therapy poststroke is as follows:
 - a. For patients with a brief transient ischemic attack and no visible infarct or hemorrhage on imaging, anticoagulation may be started within the first 24 hours post- transient ischemic attack.
 - b. For patients with a minor clinical stroke/small non-hemorrhagic infarct on imaging, anticoagulation may be started 3 days post-stroke.
 - c. For patients with a moderate clinical stroke/moderate-sized infarct on imaging (without hemorrhage on CT), anticoagulation may be started 6-7 days post-stroke.
 - d. For patients with a severe clinical stroke/large-sized infarct on imaging (without hemorrhage on CT), anticoagulation may be started 12-14 days post-stroke.
3. If anticoagulation is delayed beyond 24 hours, it is recommended to obtain repeat brain imaging for reassessment prior to initiation of anticoagulation to exclude the presence of asymptomatic hemorrhagic transformation of the index infarct.
4. It is reasonable to delay the initiation of anticoagulation for more than 2 weeks post-stroke if in the judgement of the clinician the risk of intracranial bleeding is felt to be high, e.g., for some patients with large infarcts and those with hemorrhagic transformation.

Stroke while on DOAC Therapy

- i. **(New for 2020):** For patients with atrial fibrillation who experience ischemic stroke or transient ischemic attack despite anticoagulant therapy, either continuing the current agent or switching to a different anticoagulant agent are reasonable options. At the present time, evidence is lacking to make more specific recommendations.

- ii. The routine addition of acetylsalicylic acid to chronic anticoagulant therapy is not recommended because of increased bleeding risk without clear evidence of benefit and potential for harm unless there is a specific medical indication.

7.3 Enhancing anticoagulant therapy effectiveness in practice and minimizing bleeding complications.

- i. Medication adherence should be continually assessed and reinforced for patients on all oral anticoagulants at each follow-up visit [Evidence Level B].
 - a. Patients who are prescribed a DOAC should be reassessed at intervals and educated regarding the short half-life of this class of drugs, the importance of daily medication adherence and the dangers of missed doses or prolonged interruptions of therapy [Evidence Level C].
 - b. For patients with atrial fibrillation taking warfarin, careful dosing and consistent INR monitoring is recommended to minimize adverse events; warfarin efficacy is dependent on maintaining therapeutic INR control and declines significantly when the international normalized ratio falls below 2.0 [Evidence Level A].
 - c. Patients and family members should be provided education, resources, and ongoing monitoring regarding atrial fibrillation and adherence to enhance compliance and address potential barriers in a timely way to facilitate self-management [Evidence Level C].
- ii. **(New for 2020):** For patients prescribed DOAC therapy, avoid inappropriate underdosing as it is associated with increased stroke risk [Evidence Level C].
- iii. For patients prescribed DOACs, creatinine clearance should be routinely monitored at least once annually, and when there is a change in health status [Evidence Level C].
 - a. Dose adjustments or a change in selected agent may be required based on changes in renal function if detected [Evidence Level C].
 - b. More frequent monitoring of renal function (every 6 months or more

frequently) may be considered for patients with renal impairment or a dehydrating illness for medication adjustment if required, particularly for patients receiving dabigatran [Evidence Level C].

- iv. For patients taking chronic oral anticoagulant therapy for non-valvular atrial fibrillation, the addition of antiplatelet therapy is not recommended due to increased bleeding risk unless there is a specific medical indication for antiplatelet therapy (e.g., recent vascular stent; certain mechanical heart valves) [Evidence Level B].
- v. **(New for 2020):** For patients with atrial fibrillation and chronic stable coronary artery disease (and >1-year post-PCI or CABG), the addition of an antiplatelet agent to DOAC therapy is not recommended as it increases bleeding risk without providing any significant benefit in reducing ischemic events (cardiac or cerebral) [Evidence Level B].

282

283 **SECTION 8: PERIOPERATIVE MANAGEMENT OF ANTICOAGULANT AND** 284 **ANTIPLATELET THERAPY (New for 2020)**

285 This edition features a new section on perioperative antithrombotic management – a commonly-
286 encountered issue in the stroke population and one in which practice variations abound. Our
287 recommendations are aligned with Thrombosis Canada.⁴⁹ For stroke or TIA patients who require
288 temporary interruption of chronic antiplatelet or anticoagulant therapy for an upcoming elective
289 surgery, decisions regarding the duration of therapy interruption depend on the agent and the
290 estimated bleeding risk associated with the surgery or procedure. The goal is to minimize the risk
291 of ischemic stroke while simultaneously minimizing the risk of clinically important (major)
292 bleeding. Patients should avoid unnecessary or prolonged interruptions of their antithrombotic
293 therapy. Clinicians should communicate clear instructions to patients regarding their
294 perioperative management plan before an elective procedure.

295 Because DOACs have a rapid offset (average half-life of approximately 12 hours) and a rapid
296 onset of action, the duration of DOAC interruption can be kept short to minimize the risk of
297 ischemic stroke. This approach of standardized DOAC interruption and resumption appeared
298 safe in the PAUSE study of 3,007 DOAC-treated patients; the 30-day post-operative rates of

299 arterial thromboembolism and major bleeding were <1% and <2%, respectively.⁵⁰ For patients
300 undergoing a minimal-bleed-risk procedure, anticoagulants can generally be continued without
301 interruption, with some caveats; for DOACs, it is reasonable to omit the morning DOAC dose
302 before the procedure to reduce bleeding risk.

303 **Descriptions of type of surgery or procedure and bleeding risk category:**

- 304 • A **high-bleed-risk surgery or procedure** includes major abdominal surgery (e.g., cancer
305 resection), major thoracic surgery, major orthopedic surgery, and any cardiac, spinal, or
306 intracranial surgery. Any patient having neuraxial anesthesia is classified as high-bleed-
307 risk because of the risk for spinal epidural hematomas which could cause limb paralysis.
- 308 • A **low to moderate-bleed-risk surgery or procedure** includes most surgeries that are
309 <1-hour duration and procedures that do not involve neuraxial anesthesia.
- 310 • A **minimal-bleed-risk surgery or procedure** includes tooth extractions, root canal, skin
311 biopsies, cataract surgery, and selected colonoscopies, for which anticoagulants can be
312 continued without interruption. Permanent pacemaker and internal cardiac defibrillator
313 implantation, as well as cardiac catheterization, also can be done without stopping
314 anticoagulants.

315

Section 8 Recommendations 2020

- i. Patients with atrial fibrillation or a mechanical heart valve who are receiving oral anticoagulant therapy and require a procedure associated with a **minimal risk of bleeding** (e.g., tooth extraction, skin biopsy, cataract removal, cardiac pacemaker) should not have anticoagulation interrupted around the time of the procedure [Level of Evidence B].
- ii. For patients with atrial fibrillation receiving a Direct Oral Anticoagulant (DOAC) for stroke prevention who require temporary DOAC interruption for an elective surgery or procedure, the following approach is recommended [Level of Evidence B]:
 - a. For a **low to moderate-bleed-risk** surgery or procedure, stop the DOAC the day before the procedure and the day of the procedure (i.e., skip 2 days total), and

restart the day after the procedure.

- b. For a **high-bleed-risk** surgery or procedure, stop the DOAC 2 days before the procedure, the day of the procedure, and one day after the procedure (i.e., skip 4 days total).

Note: An exception involves patients on dabigatran with impaired renal function (CrCl <50 mL/min) in whom an additional 1-2 days of interruption is suggested before surgery or procedure. Refer to clinical considerations for additional information.

- iii. For patients with atrial fibrillation receiving **warfarin** for stroke prevention who require temporary warfarin interruption for an elective surgery or procedure:
 - a. For patients at **low to moderate stroke risk** (e.g., CHADS2 score 0-4), warfarin should be stopped for 5 days pre-procedure, and resumed within 24 hours post-procedure, without heparin bridging [Level of Evidence: A].
 - b. For patients at **high stroke risk** (e.g., CHADS2 score 5-6 or prior perioperative stroke), heparin bridging is suggested during warfarin interruption, typically with twice-daily subcutaneous injections of low-molecular-weight heparin for 3 days before and 3 days after the surgery or procedure [Level of Evidence: B] If bridging is used pre-operatively, it is recommended to forego post-operative bridging in selected patients, especially those undergoing high-bleed-risk procedures [Level of Evidence: B].
- iv. For patients with a **mechanical heart valve** who are receiving warfarin for stroke prevention and require temporary warfarin interruption for elective surgery or procedure, stopping warfarin 5 days pre-procedure is recommended and should be resumed within 24 hours post-procedure [Level of Evidence: A].
 - Heparin bridging is recommended for selected patients with a mitral valve prosthesis and for high-risk patients with an aortic valve prosthesis (e.g., with additional risk factors for stroke) [Level of Evidence: B].
 - If bridging is used pre-operatively, it is recommended to forego post-operative bridging in selected patients, especially those undergoing high-bleed-risk

procedures [Level of Evidence: B].

- v. For patients receiving **acetylsalicylic acid** for stroke prevention who require an elective or urgent (within 7 days) carotid endarterectomy or coronary artery bypass surgery, acetylsalicylic acid should be continued without interruption [Level of Evidence: B].
- vi. For patients who are receiving **dual antiplatelet therapy** with acetylsalicylic acid and a P2Y12 inhibitor (e.g., clopidogrel, ticagrelor) for secondary stroke prevention who require urgent carotid endarterectomy (within 7 days), acetylsalicylic acid and a P2Y12 inhibitor should be continued perioperatively [Level of Evidence C].
- vii. For patients undergoing other types of surgery, continuing **acetylsalicylic acid** could be considered before a low/moderate-bleed-risk surgery or procedure. Interrupting **acetylsalicylic acid** before a high-bleed-risk surgery or procedure could be considered for 7-10 days [Level of Evidence C].

Section 8 Clinical Considerations

Perioperative management of patients undergoing a minimal-bleed-risk procedure

1. For patients undergoing minor procedures that are considered minimal-bleed-risk (refer to definition above), it is not routinely necessary to stop anticoagulants. However, there are some caveats to the management of such patients:
 - a. Any of the minimal-bleed-risk procedures could be considered as having a higher bleed risk warranting anticoagulant interruption (e.g., tooth extraction in a patient with poor dentition or cataract surgery with retrobulbar anesthesia) based on individual patient circumstances.
 - b. In patients receiving a DOAC who are undergoing a minimal bleed-risk procedure, it is prudent to omit the morning DOAC dose just before the procedure because the peak anticoagulant effect, occurring 1-3 hours after intake, may coincide with the timing of the procedure and may increase the risk for bleeding.
 - c. For pacemaker or ICD implantation, patients can continue warfarin, but the

international normalized ratio (INR) should be <3.0 at the time of the procedure.

- d. For coronary angiography, continuing anticoagulants if a femoral artery approach is used may not be advisable as such patients are at increased risk for developing a hematoma or false aneurysm.
- e. For colonoscopy, anticoagulation can be continued in selected patients where the likelihood of polypectomy or multiple biopsies is low.
- f. For dental procedures, oral tranexamic acid mouthwash can be used before and 2-3 times daily after the procedure to reduce bleeding since such oral bleeding, although not clinically important, may cause distress to patients.

Perioperative management of patients undergoing a moderate to high-risk procedure

1. Patients having a **high-bleed-risk** surgery or procedure only need to be off DOACs for 2 days before the procedure, corresponding to a 60–68-hour interval between the last DOAC dose and the time of surgery, which means there is little to no residual anticoagulant effect at surgery given the 12–15-hour half-life of DOACs.
2. Patients having a **low/moderate-bleed-risk** surgery or procedure only need to be off DOACs for 1 day before the procedure, corresponding to a 36–42-hour interval between the last dose and the surgery.
3. For all patients, no DOAC should be taken on the day of surgery/procedure.
4. The exception to this approach is patients on dabigatran with impaired renal function (creatinine clearance <50 mL/minute). Because dabigatran is cleared primarily by the kidneys, a longer interruption interval is needed (4 days before a high-bleed-risk surgery: 2 days before a low/moderate-bleed-risk surgery).
5. Postoperative resumption of DOACs should wait at least 24 hours after a low/moderate-bleed-risk surgery or procedure and 48-72 hours after a high-bleed-risk surgery or procedure.
6. There are caveats to postoperative DOAC management: First, the 48–72-hour resumption interval can be extended if there is greater than expected postoperative

bleeding, which is important because the full anticoagulant effect of DOAC is almost immediate after oral intake. Second, in patients who are unable to take medications by mouth and who are at high risk for venous thromboembolism, low-dose LMWH can be given for the initial 1-3 postoperative days

316

317 **Section 9: Management of extracranial carotid disease and intracranial atherosclerosis**

318 Carotid endarterectomy (CEA) has been shown to prevent stroke recurrence in patients who have
319 sustained a minor stroke or transient ischemic attack with ipsilateral high-grade carotid stenosis.
320 For those with 50% to 99% stenosis, the number of persons needed to undergo surgery to prevent
321 one ipsilateral stroke in five years was estimated to be nine for men versus. 36 for women.
322 Women with symptomatic disease had significantly higher odds of 30-day mortality following
323 CEA compared with men. (adjusted OR= 1.4, 95% CI 1.02-1.94).⁵¹

324

325 The use of CEA for asymptomatic carotid artery disease is controversial. One-year results from
326 the recent SPACE-2 trial,⁵² indicated there were no significant differences between groups (CEA
327 vs. best medical management) in the occurrences of any stroke after day 30, up to one-year,
328 ipsilateral stroke, disabling stroke, any death, myocardial infarction, restenosis or transient
329 ischemic attack. The trial was terminated early due to low recruitment. In this same trial, there
330 were no significant differences in the same outcomes for the comparison of best medical
331 management versus carotid-artery angioplasty.

332

Section 9 Recommendations 2020

9.1 Symptomatic Carotid Artery Stenosis

9.1.1 Imaging

- i. If revascularization is being considered for carotid stenosis based only on carotid ultrasound, then CTA or contrast enhanced MRA is recommended to confirm the degree of stenosis and guide surgical decision-making, as well as to assess for tandem disease [Evidence Level C].
 - a. Conversely, carotid ultrasound may be required after initial diagnosis of carotid

stenosis using CTA or contrast-enhanced MRA if heavily calcified plaque or other features make quantification of stenosis less reliable [Evidence Level C].

9.1.2 Indications for carotid revascularization

- i. Patients with a symptomatic event attributed to an ipsilateral **50 to 99** percent carotid artery stenosis should be evaluated without delay for potential carotid revascularization by a health professional with stroke expertise [Evidence Level B].
 - a. In men with **50 to 99** percent and women with **70 to 99** percent symptomatic carotid artery stenosis, carotid endarterectomy (CEA) is recommended and should be performed as soon as possible following the qualifying event [Evidence Level A].
 - b. In women with **50 to 69** percent symptomatic carotid stenosis, CEA may be considered in those at highest risk of stroke recurrence and upon consideration of other patient factors [Evidence Level B].

9.1.3 Procedures

- i. Carotid revascularization (CEA or Carotid artery stenting (CAS)) should be performed by a proceduralist/centre that routinely audits their performance results, especially perioperative stroke, and death rates [Evidence Level B].
 - a. For CEA, the randomized trials upon which these recommendations are based (benefits accrued for patients undergoing surgery within 6 months of symptoms) involved combined perioperative stroke and death rates of 6 - 7 % [Evidence Level A].
 - b. For CAS, the randomized trial upon which these recommendations are based involved combined periprocedural stroke and death rates of 5% [Evidence Level B].
- ii. Carotid endarterectomy is generally more appropriate than CAS for patients over age 70 years who are otherwise fit for surgery as current evidence indicates stenting carries a higher peri-procedural risk of stroke and death in older patients. [Evidence Level A].
- iii. Carotid stenting may be considered for patients who are not operative candidates for technical, anatomic, or medical reasons [Evidence Level A].

9.1.4 Timing

- i. In clinically stable patients (men and women), CEA should be performed as early as possible following a qualifying event [Evidence Level B] and ideally within 14 days [Evidence Level A].
- ii. In **men with 50-69** percent stenosis the benefit of CEA is greatest when performed within 14 days of the qualifying event [Evidence Level A] and is attenuated when performed beyond 14 days of the qualifying event (*Refer to Appendix Three below for summary of recurrent stroke risk at various time points*).

Section 9.1 Clinical Considerations

1. Most data regarding optimal timing of carotid revascularization for symptomatic carotid stenosis are derived from studies of CEA and not CAS. However, it may be reasonable to consider that similar recommendations regarding timing also apply to CAS.
2. In exceptional situations, if local system barriers preclude timely access to CEA while CAS is more rapidly accessible, this latter revascularization procedure may be considered in patients otherwise considered eligible for CAS. However, every effort must be made to enable local systems of care to ensure timely access to CEA.
3. It may be reasonable to consider delaying CEA beyond 48 hours of the qualifying event as surgery before this time may be associated with a higher risk of perioperative complications, particularly when the qualifying event was a stroke and not a transient ischemic attack.
4. For patients with moderate or severe stroke due to symptomatic carotid stenosis, the benefit of carotid revascularization is uncertain and should be considered on an individual basis, as such patients were excluded from trials of CEA and CAS.
5. In acute stroke patients with tandem lesions (cervical carotid stenosis or occlusion and ipsilateral intracranial large vessel occlusion) who have undergone EVT but in whom no acute CAS has been performed during the EVT procedure, subsequent carotid

revascularization by CAS and CEA should be considered if the patient otherwise remains a candidate for either procedure (as determined by residual degree of carotid stenosis, stroke severity, patient recovery, infarct size, reperfusion and bleeding risk and other factors).

9.2 Asymptomatic and Remotely Symptomatic Carotid Artery Stenosis

- i. Individuals with asymptomatic carotid artery stenosis should receive aggressive medical management of risk factors as defined throughout the *Secondary Prevention of Stroke* Module (for example, blood pressure, diabetes, cholesterol, antiplatelet therapy, smoking cessation, and lifestyle changes) [Evidence Level B].
- ii. Carotid endarterectomy may be considered for **highly selected patients with 60 to 99 percent** carotid stenosis who are asymptomatic or were remotely symptomatic (i.e., greater than six months prior to presentation) [Evidence Level A].
 - a. The benefit of carotid endarterectomy for **women with 60-99 percent** asymptomatic carotid artery stenosis is not clear and should only be considered in highly selected patients [Evidence Level B] in consultation with a health professional with stroke expertise.
 - b. Patients should be evaluated to determine eligibility for carotid endarterectomy, such as a life expectancy of more than five years, and an acceptable risk of surgical complications [Evidence Level A].
 - c. In carefully selected patients, carotid endarterectomy should be performed by a surgeon who routinely audits their performance results and demonstrates a less than 3 percent risk of peri-operative morbidity and mortality [Evidence Level B].
 - d. Important improvements in best medical therapy (control of blood pressure, lipids, diabetes, and smoking) since the major trials of endarterectomy for asymptomatic stenosis possibly make their results less applicable to contemporary management practise (Evidence Level C)
- iii. Carotid stenting may be considered in patients with **60 to 99 percent asymptomatic**

carotid stenosis who are not operative candidates for technical, anatomic or medical reasons provided there is a less than 3 percent risk of peri-procedural morbidity and mortality [Evidence Level A].

Section 9.2 Clinical Considerations:

1. Although their impact on clinical decision-making regarding revascularization of asymptomatic patients is uncertain, several factors may confer a higher risk of stroke in patients with asymptomatic stenosis, including:
 - a. Progression of stenosis over time
 - b. Ipsilateral covert brain infarcts on imaging
 - c. Ipsilateral intracranial embolization detected on transcranial Doppler
 - d. Plaque morphology on non-invasive imaging (ex. volume, echolucency, intraplaque hemorrhage)

9.3 Symptomatic Vertebral Artery Stenosis

- i. **(New for 2020):** For patients with symptomatic vertebral artery stenosis (extracranial or intracranial), medical therapy is recommended over stenting for secondary stroke prevention [Evidence Level B].

9.4 Symptomatic Intracranial Artery Stenosis

- i. For patients with a recent ischemic stroke or transient ischemic attack due to symptomatic **intracranial artery stenosis of 70-99 percent**, medical therapy is recommended over stenting for secondary stroke prevention [Evidence Level B].

Note: The SAMMPRIS protocol consisted of 3 months of dual antiplatelet therapy with acetylsalicylic acid and clopidogrel (excluding high bleeding risk patients), and is typically followed by antiplatelet monotherapy thereafter, plus intensive lipid-lowering therapy with high-dose statin, blood pressure treatment, and structured lifestyle modification addressing smoking cessation, exercise and diet.

- ii. In patients who have been managed with maximal medical therapy in the presence of

intracranial stenosis and experience a recurrent stroke, there is lack of evidence to guide management decisions; intracranial angioplasty (with or without stenting) may be reasonable in carefully selected patients [Evidence Level C].

9.5 Cervicocephalic Artery Dissection

- i. **(New for 2020):** For patients with ischemic stroke or transient ischemic attack that is preceded by head/neck trauma, cervical spine mechanical trigger event, or prominent head/neck pain, a diagnosis of carotid or vertebral artery dissection should be suspected [Evidence Level C].
- ii. For patients with ischemic stroke or transient ischemic attack in whom a carotid or vertebral artery dissection is suspected, CTA or MRA of the head and neck (or catheter angiogram) is recommended as the diagnostic neurovascular imaging test rather than ultrasound [Evidence Level C].

Note: CTA or MRA are the preferred non-invasive diagnostic imaging tests for patients with a suspected cervicocephalic artery dissection, as neck ultrasound does not fully visualize the vertebral arteries and can miss distal carotid artery dissections originating above the angle of the jaw.

- iii. Antithrombotic therapy for stroke prevention is recommended for individuals with a diagnosis of an acute or recent extracranial carotid or vertebral artery dissection [Evidence Level B].
 - a. **(New for 2020):** There is uncertainty about the comparative efficacy of antiplatelet therapy vs. anticoagulation with heparin or warfarin; either treatment is considered reasonable based on current evidence [Evidence Level B]; decisions should be based on individual risk/benefit analysis taking into consideration the imaging features of the dissection (presence and degree of stenosis, intraluminal thrombus, vessel occlusion, pseudoaneurysm), brain imaging, patient characteristics, and estimated bleeding risk [Evidence Level C].
 - b. The optimal duration of antithrombotic therapy post-dissection is uncertain; decisions may be based on individual clinical factors and imaging appearances

on follow-up vascular imaging [Evidence Level C].

- iv. There is a lack of evidence regarding the safety and efficacy of anticoagulation for intracranial arterial dissections and treatment decisions should be individualized [Evidence Level C].

Section 9.5 Clinical Considerations

1. There is insufficient evidence at this time to make a recommendation regarding the use of DOACs in patients with arterial dissections [Evidence Level C].

333

334 Section 10: Other cardiac issues in individuals with stroke

335 Since the last edition, a new randomized trial⁵³ and additional meta-analyses and other reports
336 further support patent foramen ovale (PFO) closure for secondary stroke prevention in selected
337 patients.⁵⁴⁻⁵⁶ Given that TIA can be difficult to differentiate from mimics and the fact that only
338 one of the PFO trials enrolled patients with TIA as an index event, clinicians should be cautious
339 when contemplating PFO closure for TIA unless there is a high certainty of ischemia;
340 accordingly, these 2021 recommendations no longer indicate TIA as an unqualified indication
341 for closure. There is now moderate-strength evidence that PFO closure may be targeted to patient
342 groups with higher risk echocardiographic features.

343 For patients with heart failure and without atrial fibrillation, the COMMANDER-HF trial,⁵⁷
344 which compared rivaroxaban to standard care, found no significant difference in the frequency of
345 the primary outcome (a composite of death from any cause, MI, or stroke) between groups. The
346 risks of the individual components of the primary outcome did not differ between groups with
347 the exception of the risk of stroke, which was reduced significantly with rivaroxaban (1.08 vs.
348 1.63 events/100-person years; HR=0.66, 95% CI 0.47–0.95). In the WARCEF trial,⁵⁸ which
349 compared the effectiveness of anticoagulation compared with antiplatelet therapy for stroke
350 prevention in patients with heart failure in sinus rhythm, warfarin was associated with a
351 significantly reduced risk of ischemic stroke (HR=0.52, 95% CI 0.33-0.82, p=0.005); however,
352 the risks of major and minor hemorrhages were significantly increased.⁵⁹

353

Section 10 Recommendations

10.1 Patent Foramen Ovale (PFO)

- i. Patients with a recent ischemic stroke suspected to be related to a PFO should have an evaluation by healthcare professionals with stroke and cardiovascular expertise [Evidence Level C].
- ii. For carefully selected patients with a recent ischemic stroke attributed to a PFO, PFO device closure plus long-term antiplatelet therapy is recommended over long-term antithrombotic therapy alone **provided all** the following criteria are met [Evidence Level A]:
 - a. Age 18-60 years.
 - b. The diagnosis of the index stroke event is confirmed by imaging as a non-lacunar embolic ischemic stroke.
 - c. The patient has been evaluated by a neurologist or healthcare professional with stroke expertise, and the PFO is felt to be the most likely cause for the index stroke event following a thorough etiological evaluation that has excluded alternate likely etiologies.
- iii. **(New for 2020):** It is reasonable to recommend against PFO closure for patients who have none of the following higher-risk anatomical features on echocardiography: (a) atrial septal aneurysm; (b) large right-to-left shunt (e.g., >20 microbubbles); and (c) large diameter PFO (e.g., ≥ 2 mm) [Evidence Level B].
- iv. For patients requiring long-term anticoagulation for other reasons, the benefit of PFO closure is uncertain, and treatment decisions should be based on individual patient characteristics and risk versus benefit profile [Evidence Level C].
- v. For patients with a recent ischemic stroke attributed to a PFO who do not undergo PFO closure and are aged 60 years or younger, either antiplatelet or anticoagulant therapy is recommended for secondary stroke prevention, unless there is a separate evidence-based indication for chronic anticoagulant therapy [Evidence Level B].

Section 10.1 Clinical Considerations

1. Warfarin can reduce recurrent stroke; however, this benefit may be outweighed by the increased risk of major hemorrhage.
2. The role of DOACs is unknown in this population.

10.2 Aortic Arch Atheroma:

- i. Aortic arch atheroma should be managed according to the stroke prevention recommendations included in all relevant sections of the *Secondary Prevention of Stroke Module* [Evidence Level C].
- ii. In the ARCH trial, no significant difference was found in individuals treated with dual antiplatelet therapy (acetylsalicylic acid plus clopidogrel) as compared with warfarin; the effectiveness of anticoagulant therapy compared with antiplatelet therapy in this context is uncertain and the choice should be individualized [Evidence Level B].

10.3 Heart Failure, Decreased Left Ventricular Ejection Fraction, Cardiac Thrombus

- i. For patients with ischemic stroke or transient ischemic attack who are in sinus rhythm and have a left atrial or left ventricular thrombus demonstrated by echocardiography or other imaging modality, anticoagulant therapy is recommended for greater than 3 months [Evidence Level C].
- ii. For patients with ischemic stroke or transient ischemic attack who are in sinus rhythm and have severe left ventricular dysfunction (ejection fraction $\leq 35\%$) without evidence of left atrial or left ventricular thrombus, the net benefit of anticoagulant therapy (with either vitamin K antagonists or DOACs) compared with antiplatelet therapy is uncertain, and the choice of management strategies should be individualized [Evidence Level B].

356 **Section 11: Cancer-associated ischemic stroke**

357 A diagnosis of cancer can increase the risk of stroke in the months or years following the
358 diagnosis, particularly among persons with lung cancer or with more advanced cancers.^{60, 61}

359 Thrombosis is a common complication of malignancy and represents a frequent cause of death in
360 cancer patients with a history of stroke.

Section 11 Recommendations

11.1 Cancer-Associated Ischemic Stroke

- i. Patients with active malignancy who experience an arterial ischemic stroke or transient ischemic attack should undergo a standard etiological work-up for their stroke, including vascular imaging and cardiac rhythm monitoring [Evidence Level C]. *Refer to Section 10 on Stroke Investigations for additional information.*
- ii. Stroke mechanisms associated with malignancy may be considered when determining etiological investigations, including non-bacterial (marantic) endocarditis, hypercoagulability, paradoxical embolism due to venous thrombosis, tumor-related vascular compression, and stroke related to anti-cancer treatments [Evidence Level C].
- iii. In patients with active malignancy and arterial ischemic stroke or transient ischemic attack in whom a cancer-associated hypercoagulable state may have contributed to the stroke, anticoagulation could be considered over antiplatelet therapy [Evidence Level C].
 - a. When anticoagulation is used, low-molecular weight heparin therapy is preferred [Evidence Level C]. The role of direct oral anticoagulants is unknown but under study and may be reasonable after consideration of patient preference.

Section 11 Clinical considerations

1. Management decisions for these patients should be made in collaboration with a health professional with expertise in Hematology, Oncology or Thrombosis, and should take into account the type of underlying cancer, the risk of bleeding, the extent of neoplastic disease, the patient's overall prognosis and expressed goals of care.
2. In patients with active malignancy and arterial ischemic stroke or transient ischemic attack with a concurrent venous thromboembolism (deep vein thrombosis or pulmonary

embolism) in whom the stroke is presumed to be due to a paradoxical embolus, anticoagulation for secondary prevention should follow guidelines for the management of DVT and PE in cancer patients which includes low molecular weight heparin (LMWH) and selected DOACs (Refer to www.thrombosiscanada.ca).

361

362 **Challenges and Future Directions**

363 Advances in stroke prevention, driven by high-quality clinical studies, continue to inform each
364 new edition of these guidelines. However, we are still far from adequately addressing, at a global
365 level, the ten modifiable risk factors that account for 90% of the population attributable risk of
366 stroke.⁶² The largest impact on stroke prevention globally will likely be achieved by continued
367 large-scale efforts to address hypertension, diabetes, diet, exercise, smoking, in addition to atrial
368 fibrillation at both policy and individual levels.

369 An key tenet of secondary stroke prevention remains the importance of identifying the most
370 likely stroke etiology and tailoring therapy accordingly. While the completed ESUS trials found
371 no overall benefit of anticoagulation, further research aims to identify whether specific
372 subgroups may benefit. Dual pathway inhibition is a promising strategy.⁶³ Newer anticoagulants
373 targeting Factor XI represent promising future treatments for stroke prevention. Studies are
374 ongoing (NCT02604667) and others are needed to better define when and how occult cancer
375 should be investigated in cryptogenic stroke patients, and if found, what antithrombotic regimen
376 best protects these patients from recurrent arterial strokes.⁶⁴

377 Immediate challenges to optimal secondary stroke prevention would therefore include the need
378 to develop, grow and maintain systems for virtual delivery of care to patients through
379 telemedicine.^{65, 66} The SARS-CoV2 virus represents a well-documented challenge to acute
380 stroke care⁶⁷ but its impact on the risk of stroke recurrence, either directly among patients
381 having been infected with the virus, or on other patients who have suffered collateral damage
382 from diminished access to stroke care, will be important to now study.

383 A challenge that concerns research in all fields of medicine, including stroke,⁶⁸ is the need to
384 ensure adequate sex and gender representation in therapeutic trials to ensure generalizability of
385 results to both men and women. This edition is the first of our guidelines to start incorporating a

386 sex and gender descriptive analysis into the literature review for each recommendation, and
387 future editions will strive to include gender and sex-based recommendations where appropriate.

388 **Summary**

389 The 2020 update of the *Canadian Stroke Best Practice Secondary Prevention of Stroke*
390 *Recommendations* provide a common set of guiding principles for important aspects of
391 secondary stroke prevention, emphasizing that individuals who have experienced a stroke or TIA
392 require access expert prevention care in a timely way. In Canada, coordinated systems have
393 evolved over time, growing the number of stroke prevention services and protocols to increase
394 access in many under-serviced areas. In the age of Covid-19, there are new opportunities to
395 provide prevention interventions remotely to narrow the inequities in access to care.

396 **Declaration of Conflicts of Interest**

397 The following authors have identified actual or potential conflicts of interest which have been
398 mitigated through the design of a multidisciplinary writing group model and additional measures
399 by the advisory committee as required. *David J. Gladstone* received a Mid-Career Investigator
400 Award from the Heart and Stroke Foundation, a peer-reviewed provincial operating grant from
401 Ontario Genomics; all funds paid to his institution to support the project (no personal fees);
402 Independent Medical Safety Monitor for the NINDS-sponsored ARCADIA trial
403 (uncompensated), and local site PI for the NASPAF-ICH and ENRICH-AF trials (with all site
404 fees paid to his institution; no personal fees); served as PI of the SCREEN-AF trial
405 (uncompensated); operating grant from the Canadian Stroke Prevention Intervention Network
406 (C-SPIN), a peer-reviewed Canadian Institutes of Health Research [CIHR]) national network
407 grant; Adjudication Committee SAFE-HD trial (uncompensated); and is the Site Investigator for
408 NAVIGATE ESUS trial and NASPAF-ICH trial (all site fees paid to my institution); Co-Leader
409 of NAVIGATE ESUS atrial myopathy/atrial fibrillation working group (uncompensated).
410 *Alexandre Y Poppe* is Site PI and Site co-investigator for ESCAPE-NA1 (NoNo), NAVIGATE-
411 ESUS (Bayer), RESPECT-ESUS (Boehringer-Ingelheim), POINT (NIH); DSMB for FLOW;
412 Canadian Stroke Trials for Optimized Results (CaSTOR) networking grant; Chair, Canadian
413 Stroke Consortium National Stroke Fellowship Program; receives support for fellowship
414 program from Servier; and research grant support from Stryker. *Jafna Cox* is a Medical
415 Consultant (received payment) for Bayer, HLS Therapeutics, Novartis; Lecture Series (received

416 payment) with Bayer; holds an Investigator-initiated grant from Bayer; and participating in a
417 Phase II study of a Factor XI inhibitor, funded by Bayer. *James Douketis is an* Advisory Board
418 Consultant for BMS Pfizer, Servier, Leo Pharma, Sanofi, Bayer; holds a grant/Honorarium from
419 Thrombosis Canada (non-profit); participation in PAUSE trial. Monies received as personal fees
420 from Janssen, Pfizer, Bayer, Bristol Myers Squibb, Sanofi, Servier Canada, Portola are deposited
421 in hospital-based (St. Joseph's Healthcare Hamilton) and university-based (McMaster
422 University) research accounts and/or charitable foundations. *Brett R. Graham holds a* Canadian
423 Stroke Consortium Catalytic Research Capacity Generation Grant; is site PI University of British
424 Columbia, University of Calgary - SECRET and TOPSECRET; site sub-I for TEMPO-2 an
425 ESCAPE NA1. Honorarium received from Servier Canada (to give a talk on anticoagulation in
426 afib to family physicians. *Marilyn Labrie is an* advisory board member for Teva Canada –
427 Fremanezumab 2020-08-23. *Jennifer Mandzia is an* advisory board with Bayer; and is clinical
428 trial Site PI for several studies. *Daniel Ngui is a* member of the Advisory Board for Amgen,
429 Astra Zeneca, BMS, BI, Lilly, Novonordisk; moderating and speaking engagements for Amgen,
430 Astra Zeneca, BMS, BI, Lilly, Novonordisk; EMR grants and audits for Amgen, Astra Zeneca,
431 BI, Novartis; holds research grants from Simple Trial, Amgen 20170191 trial, IHE eCare CV
432 Risk , CHRC EMR Registry Trials: AF OAC, Advantage CV, and Advantage OP-Phase 4 and
433 EMR audits; Health Choices First Video Education shares; Investments in communications
434 companies including CHRC, CCRN, MD Briefcase, Medplan, Liv Agency, Four Health; board
435 membership on CCS Lipid guideline Panel, CCS A. fib guideline 2nd Panel, SPH Hospital CME
436 Committee, BC Guidelines, UBC CPD CME “This changed my practice”, Alliance for Best
437 Practices in Health Education. *William Semchuk is an* Advisory Board Member for BMS Pfizer;
438 Speaker Honorarium from BMS, Pfizer, Astra Zeneca, Sanofi, Servier, Bayer, BI. *Jacob A Udell*
439 is an advisory board member for Boehringer-Ingelheim, Novartis, Sanofi; Secondary analysis of
440 banked biospecimens from a completed RCT for Janssen; Consultant on clinical research
441 development, (no involvement in marketing) with Boehringer Ingelheim, Janssen, Sanofi,
442 Amgen, Merck, Novartis; received grant to University Health Network for clinical trial from
443 AstraZeneca; grant to University Health Network for clinical trial and honorarium for leadership
444 of a multicenter RCT from Boehringer-Ingelheim; grant to Women’s College Hospital for
445 clinical research study from Janssen; grant to Women’s College Hospital to be a site in a
446 multicenter RCT and honorarium for steering committee membership in cohort study by

447 Novartis; grant to Women's College Hospital for site participation in a multicenter RCT and
448 honorarium for national co-PI role in multicenter RCT for Sanofi; grants to his institutions for
449 clinical trial participation from Boehringer-Ingelheim, Novartis, Sanofi; grant from Bayer.
450 *Stephen van Gaal site investigator* enrolls patients for Portola, Bayer; advisory board member for
451 Servier (edoxaban); support for conference attendance from Bayer (rivaroxaban); Canadian
452 Stroke Consortium committee member. *Karina Villaluna is a Clinical Research Coordinator*
453 participating in research for NoNO Inc, Portola and BMS. Eric E Smith participates in consulting
454 for clinical trials in cerebral amyloid angiopathy, vascular cognitive impairment, and preventing
455 atrial fibrillation-related stroke with Bayer, Biogen, Javelin; Royalties from UpToDate for
456 chapter on diagnosing vascular dementia; and is Study site for Biogen study on adacatumab for
457 Alzheimer's disease. *Dar Dowlatshahi* holds a Heart & Stroke Foundation of Canada Research
458 Grant and Salary Award; a Patent for CARL for detection of contrast extravasation; and is
459 involved in several funded clinical trials; member, Canadian Stroke Consortium board of
460 directors. Theodore Wein is a consultant for Servier, Allergan Inc, Ipsen Inc; a speaker for
461 Servier; receives research funding from Allergan and Servier; and is PI on a Servier funded
462 study. Shelagh Coutt^s holds a current CIHR grant. *Gord Gubitza is an Advisory Board member* for
463 Bayer, BI, Pfizer; Member, DSMB CATIS-ICAD trial; Member, Steering Committee. HSF
464 Canada Stroke Best Practices; Co-Chair, World Stroke Organization Education Committee;
465 Atlantic Canada Together Enhancing Acute Stroke Treatment (ACTEAST): Improving Access
466 and Efficiency of Treatment. Co-Investigator. Canadian Institutes of Health Research (CIHR)
467 Project Grant; Optimization and Validation of a Novel Emergency Department Point-of-Care
468 MRI. Nova Scotia Health Research Foundation. Research Nova Scotia Trust, Industry
469 collaborator; The effects of prism adaptation training on visual attention and functional activities
470 in stroke patients with neglect. Nova Scotia Health Research Foundation – Establishment Grant.
471 *Paul Pageau* is a Past board member, Canadian Association of Emergency Physicians. The
472 following authors have no conflicts of interest to declare: M. Patrice Lindsay, Anita Mountain,
473 Aline Bourgoin, John B. Falconer, Norine Foley, Lena McDonald, Rebecca McGuff, Amanda
474 Rodgerson, Tammy Tebbutt, and Carmen Tuchak.

475 **Acknowledgements**

476 Heart &Stroke gratefully acknowledges the *Secondary Prevention of Stroke* writing group
477 leaders and members all of whom have volunteered their time and expertise to the update of
478 these recommendations. Members of the Canadian Stroke Consortium were involved in all
479 aspects of the development of these recommendations. These recommendations (in whole or
480 specific parts) underwent external review by: Jason Andrade, Rohit Bhatia, Margie Burns, Elena
481 Adela Cora, Roxanne Cournoyer, Laurent Derex, Paul Dorian, Charles Duffy, Eric Ehrensperger,
482 Yuriy Flomin, Kirsten George-Phillips, Sarah Grant, Milan Gupta, Rahul Jain, Shirin Jalani,
483 Glen Jickling, Hooman Kamel, Hong Kao, Puneet Kapur, Lisa Keon, Lisa Korec, Catherine
484 Legault, Gerald MacDonald, GB John Mancini, Michael MacDonald, Kaylee Murphy, Kelvin
485 Kuan Huei Ng, Darlene Peacock, Andre Roussin, Joanna D Schaafsma, Peter Senior, Aleksander
486 Tkach, Sean Virani, Elissa Weinberg, Heather Williams, and Janice Williams. We thank the
487 Canadian Stroke Best Practices and Quality Advisory Committee members, including Eric Smith
488 (Co-Chair), Anita Mountain (Co-Chair), Leanne Casaubon, Gord Gubitz, Dar Dowlatshahi,
489 Dylan Blacquiére, Louise Clement, Thalia Field, Farrell Leibovitch, Christine Papoushek,
490 Jeffrey Habert, Barbara Campbell, Joyce Fung, Michael Hill, Tim Hillier, Thomas Jeerakathil,
491 Eddy Lang, Pascale Lavoie, Beth Linkewich, Colleen O’Connell, Melanie Penn, Jai Shankar,
492 Debbie Timpson, Theodore Wein, and Katie White. We acknowledge and thank Norine Foley
493 and the evidence analysis team at workHORSE; Laurie Charest of Heart & Stroke for her
494 coordination of the CSBPR teams and processes; Andrea deJong, Francine Forget Marin, and the
495 Heart & Stroke internal teams who contributed to the development of these recommendations
496 and publication: Communications, Translation, Knowledge Translation, Engagement, Health
497 Policy and Digital Solutions. Heart & Stroke is especially grateful to the members of the
498 Community Consultation and Review Panel who reviewed all sections of this module, shared
499 their personal experiences and insights on what did or would have made their journey optimal.
500 The members of the Secondary Prevention of Stroke CCRP included: Cheryl Beattie, Jennifer
501 Bogart, Dan Dobbin, Glen Hilton, Judy Hilton, Allan Morrison and additional volunteers who
502 reviewed all sections and provided input and developed patient infographic resources.

503 **Funding**

504 The development of the *CSBPR* is funded in its entirety by Heart & Stroke. No funds for the
505 development of these guidelines come from commercial interests, including pharmaceutical
506 and device companies. All members of the recommendation writing groups, and external
507 reviewers are volunteers and do not receive any remuneration for participation in guideline
508 development, updates, and reviews. All participants complete a conflict of interest declaration
509 prior to participation.

510

511 **References**

- 512 1. Graham ID, Harrison MB, Brouwers M, Davies BL and Dunn S. Facilitating the use of
513 evidence in practice: evaluating and adapting clinical practice guidelines for local use by
514 health care organizations. *Journal of obstetric, gynecologic, and neonatal nursing* :
515 *JOGNN* 2002; 31: 599-611. 2002/10/02.
- 516 2. Vernooij RW, Alonso-Coello P, Brouwers M and Martinez Garcia L. Reporting Items for
517 Updated Clinical Guidelines: Checklist for the Reporting of Updated Guidelines
518 (CheckUp). *PLoS medicine* 2017; 14: e1002207. 2017/01/11. DOI:
519 10.1371/journal.pmed.1002207.
- 520 3. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline
521 development, reporting and evaluation in health care. *CMAJ : Canadian Medical*
522 *Association journal = journal de l'Association medicale canadienne* 2010; 182: E839-842.
523 2010/07/07. DOI: 10.1503/cmaj.090449.
- 524 4. Coutts SB, Wein TH, Lindsay MP, et al. Canadian Stroke Best Practice Recommendations:
525 Secondary prevention of stroke guidelines, update 2014. *International journal of stroke :*
526 *official journal of the International Stroke Society* 2015; 10: 282-291. 2014/12/24. DOI:
527 10.1111/ijss.12439.
- 528 5. Wein T, Lindsay MP, Cote R, et al. Canadian Stroke Best Practice Recommendations:
529 Secondary Prevention of Stroke, Sixth Edition Practice Guidelines, update 2017.
530 *International journal of stroke : official journal of the International Stroke Society* 2018;
531 13: 420-443. 2017/11/25. DOI: 10.1177/1747493017743062.
- 532 6. Lindsay MP, Gierman N, Harris JE, et al. People with lived experience at the centre of
533 Canadian Stroke Best Practice Recommendations: A Model for Guideline Developers. *J*
534 *Patient Exp* 2020; 7: 951-956. 2021/01/19. DOI: 10.1177/2374373520956538.
- 535 7. Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient
536 ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a
537 prospective population-based sequential comparison. *Lancet (London, England)* 2007; 370:
538 1432-1442. 2007/10/12. DOI: 10.1016/s0140-6736(07)61448-2.

- 539 8. Lioutas VA, Ivan CS, Himali JJ, et al. Incidence of transient ischemic attack and
540 association with long-term risk of stroke. *Jama* 2021; 325: 373-381. 2021/01/27. DOI:
541 10.1001/jama.2020.25071.
- 542 9. Kamal N, Hill MD, Blacchiere DP, et al. Rapid assessment and treatment of transient
543 ischemic attacks and minor stroke in Canadian Emergency Departments: Time for a
544 paradigm shift. *Stroke* 2015; 46: 2987-2990. 2015/09/01. DOI:
545 10.1161/strokeaha.115.010454.
- 546 10. Schnabel RB, Haeusler KG, Healey JS, et al. Searching for atrial fibrillation poststroke: a
547 white paper of the AF-SCREEN International Collaboration. *Circulation* 2019; 140: 1834-
548 1850. 2019/11/26. DOI: 10.1161/circulationaha.119.040267.
- 549 11. Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada's 2020
550 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment
551 of Hypertension in Adults and Children. *Canadian Journal of Cardiology* 2020; 36: 596-
552 624. DOI: 10.1016/j.cjca.2020.02.086.
- 553 12. Salisbury C, O'Cathain A, Thomas C, et al. Telehealth for patients at high risk of
554 cardiovascular disease: pragmatic randomised controlled trial. *BMJ (Clinical research ed)*
555 2016; 353: i2647. 2016/06/03. DOI: 10.1136/bmj.i2647.
- 556 13. Liu S, Feng W, Chhatbar PY, Liu Y, Ji X and Ovbiagele B. Mobile health as a viable
557 strategy to enhance stroke risk factor control: A systematic review and meta-analysis.
558 *Journal of the neurological sciences* 2017; 378: 140-145. 2017/06/02. DOI:
559 10.1016/j.jns.2017.04.050.
- 560 14. Widmer RJ, Collins NM, Collins CS, West CP, Lerman LO and Lerman A. Digital health
561 interventions for the prevention of cardiovascular disease: a systematic review and meta-
562 analysis. *Mayo Clinic proceedings* 2015; 90: 469-480. 2015/04/07. DOI:
563 10.1016/j.mayocp.2014.12.026.
- 564 15. Kapoor A, Lindsay MP, Yu AYY, et al. Call 911: Lower ambulance utilization among
565 young adults, especially women, with stroke. *Can J Neurol Sci* 2020; 47: 764-769.
566 2020/06/09. DOI: 10.1017/cjn.2020.119.

- 567 16. Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial of e-cigarettes versus
568 nicotine-replacement therapy. *The New England journal of medicine* 2019 2019/01/31.
569 DOI: 10.1056/NEJMoa1808779.
- 570 17. McClester M, Mounsey A and Mackler L. Clinical inquiry: Do oral contraceptives carry a
571 significant risk of stroke for women with migraines? *J Fam Pract* 2013; 62: 662-663.
572 2013/11/30.
- 573 18. Feigin VL, Roth GA, Naghavi M, et al. Global burden of stroke and risk factors in 188
574 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study
575 2013. *The Lancet Neurology* 2016; 15: 913-924. 2016/06/14. DOI: 10.1016/s1474-
576 4422(16)30073-4.
- 577 19. Law MR, Morris JK and Wald NJ. Use of blood pressure lowering drugs in the prevention
578 of cardiovascular disease: meta-analysis of 147 randomised trials in the context of
579 expectations from prospective epidemiological studies. *BMJ (Clinical research ed)* 2009;
580 338: b1665. 2009/05/21. DOI: 10.1136/bmj.b1665.
- 581 20. Kitagawa K, Yamamoto Y, Arima H, et al. Effect of standard vs intensive blood pressure
582 control on the risk of recurrent stroke: A randomized clinical trial and meta-analysis.
583 *JAMA neurology* 2019 2019/07/30. DOI: 10.1001/jamaneuro.2019.2167.
- 584 21. Amarenco P, Kim JS, Labreuche J, et al. A Comparison of two ldl cholesterol targets after
585 ischemic stroke. *The New England journal of medicine* 2019 2019/11/19. DOI:
586 10.1056/NEJMoa1910355.
- 587 22. Shoamanesh A, Patrice Lindsay M, Castellucci LA, et al. Canadian stroke Best Practice
588 Recommendations: Management of Spontaneous Intracerebral Hemorrhage, 7th Edition
589 Update 2020. *International journal of stroke : official journal of the International Stroke*
590 *Society* 2020: 1747493020968424. 2020/11/12. DOI: 10.1177/1747493020968424.
- 591 23. Global Burden of Disease Results Tool. <http://ghdx.healthdata.org/gbd-results-tool>
592 (Accessed: November 15, 2020).
- 593 24. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose
594 concentration, and risk of vascular disease: a collaborative meta-analysis of 102

- 595 prospective studies. *Lancet (London, England)* 2010; 375: 2215-2222. 2010/07/09. DOI:
596 10.1016/s0140-6736(10)60484-9.
- 597 25. Group AtCCRiDS. Effects of intensive glucose lowering in type 2 diabetes. *The New*
598 *England journal of medicine* 2008; 2008: 2545-2559.
- 599 26. Duckworth W, Abaira C, Moritz T, et al. Glucose control and vascular complications in
600 veterans with type 2 diabetes. *New England Journal of Medicine* 2009; 360: 129-139.
- 601 27. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes
602 and nephropathy. *The New England journal of medicine* 2019; 380: 2295-2306.
603 2019/04/17. DOI: 10.1056/NEJMoa1811744.
- 604 28. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in
605 type 2 diabetes. *The New England journal of medicine* 2020; 383: 1425-1435. 2020/09/24.
606 DOI: 10.1056/NEJMoa2004967.
- 607 29. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes
608 in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*
609 *(London, England)* 2019 2019/06/14. DOI: 10.1016/s0140-6736(19)31149-3.
- 610 30. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular
611 outcomes in patients with type 2 diabetes. *The New England journal of medicine* 2019
612 2019/06/12. DOI: 10.1056/NEJMoa1901118.
- 613 31. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major
614 cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk:
615 The CARMELINA Randomized Clinical Trial. *Jama* 2019; 321: 69-79. 2018/11/13. DOI:
616 10.1001/jama.2018.18269.
- 617 32. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient
618 ischemic attack. *The New England journal of medicine* 2016; 374: 1321-1331. 2016/02/18.
619 DOI: 10.1056/NEJMoa1506930.
- 620 33. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke
621 and high-risk TIA. *The New England journal of medicine* 2018; 379: 215-225. 2018/05/17.
622 DOI: 10.1056/NEJMoa1800410.

- 623 34. Wong KS, Wang Y, Leng X, et al. Early dual versus mono antiplatelet therapy for acute
624 non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic
625 review and meta-analysis. *Circulation* 2013; 128: 1656-1666. 2013/09/14. DOI:
626 10.1161/circulationaha.113.003187.
- 627 35. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM and Buchan AM. Fast
628 assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER):
629 a randomised controlled pilot trial. *The Lancet Neurology* 2007; 6: 961-969. 2007/10/13.
630 DOI: 10.1016/s1474-4422(07)70250-8.
- 631 36. Pan Y, Elm JJ, Li H, et al. Outcomes associated with clopidogrel-aspirin use in minor
632 stroke or transient ischemic attack: A Pooled Analysis of Clopidogrel in High-Risk
633 Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-
634 Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. *JAMA*
635 *neurology* 2019 2019/08/20. DOI: 10.1001/jamaneurol.2019.2531.
- 636 37. Hao Q, Tampi M, O'Donnell M, Foroutan F, Siemieniuk RA and Guyatt G. Clopidogrel
637 plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient
638 ischaemic attack: systematic review and meta-analysis. *BMJ (Clinical research ed)* 2018;
639 363: k5108. 2018/12/20. DOI: 10.1136/bmj.k5108.
- 640 38. Pereira NL, Farkouh ME, So D, et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor
641 Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous
642 Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. *Jama* 2020; 324:
643 761-771. 2020/08/26. DOI: 10.1001/jama.2020.12443.
- 644 39. Wang Y, Zhao X, Lin J, et al. Association Between CYP2C19 Loss-of-Function Allele
645 Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke
646 or Transient Ischemic Attack. *Jama* 2016; 316: 70-78. 2016/06/28. DOI:
647 10.1001/jama.2016.8662.
- 648 40. Meschia JF, Walton RL, Farrugia LP, et al. Efficacy of Clopidogrel for Prevention of
649 Stroke Based on CYP2C19 Allele Status in the POINT Trial. *Stroke* 2020; 51: 2058-2065.
650 2020/06/23. DOI: 10.1161/strokeaha.119.028713.

- 651 41. Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and Aspirin or Aspirin Alone in
652 Acute Ischemic Stroke or TIA. *The New England journal of medicine* 2020; 383: 207-217.
653 2020/07/16. DOI: 10.1056/NEJMoa1916870.
- 654 42. Amarenco P, Denison H, Evans SR, et al. Ticagrelor Added to Aspirin in Acute Nonsevere
655 Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. *Stroke* 2020; 51:
656 3504-3513. 2020/11/18. DOI: 10.1161/strokeaha.120.032239.
- 657 43. Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: the case
658 for a new clinical construct. *The Lancet Neurology* 2014; 13: 429-438. 2014/03/22. DOI:
659 10.1016/s1474-4422(13)70310-7.
- 660 44. Diener HC, Sacco RL, Easton JD, et al. Dabigatran for Prevention of Stroke after Embolic
661 Stroke of Undetermined Source. *The New England journal of medicine* 2019; 380: 1906-
662 1917. 2019/05/16. DOI: 10.1056/NEJMoa1813959.
- 663 45. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or
664 minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. *Lancet (London,*
665 *England)* 1993; 342: 1255-1262. 1993/11/20.
- 666 46. Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian Cardiovascular
667 Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management
668 of Atrial Fibrillation. *The Canadian journal of cardiology* 2020; 36: 1847-1948.
669 2020/11/17. DOI: 10.1016/j.cjca.2020.09.001.
- 670 47. Guimarães HP, Lopes RD, de Barros ESPGM, et al. Rivaroxaban in Patients with Atrial
671 Fibrillation and a Bioprosthetic Mitral Valve. *The New England journal of medicine* 2020;
672 383: 2117-2126. 2020/11/17. DOI: 10.1056/NEJMoa2029603.
- 673 48. Yasuda S, Kaikita K, Akao M, et al. Antithrombotic Therapy for Atrial Fibrillation with
674 Stable Coronary Disease. *New England Journal of Medicine* 2019; 381: 1103-1113. DOI:
675 10.1056/NEJMoa1904143.
- 676 49. Thrombosis Canada. NOACs DOACs: Perioperative Management (May 2020).
677 [https://thrombosiscanada.ca/wp-uploads/uploads/2021/01/22.-NOACs-DOACs-](https://thrombosiscanada.ca/wp-uploads/uploads/2021/01/22.-NOACs-DOACs-Perioperative-Management-17May2020.pdf)
678 [Perioperative-Management-17May2020.pdf](https://thrombosiscanada.ca/wp-uploads/uploads/2021/01/22.-NOACs-DOACs-Perioperative-Management-17May2020.pdf). (Accessed December 15, 2020).

- 679 50. Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative Management of Patients
680 With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. *JAMA internal medicine*
681 2019 2019/08/06. DOI: 10.1001/jamainternmed.2019.2431.
- 682 51. Dansey KD, Pothof AB, Zettervall SL, et al. Clinical impact of sex on carotid
683 revascularization. *J Vasc Surg* 2020; 71: 1587-1594.e1582. 2020/02/06. DOI:
684 10.1016/j.jvs.2019.07.088.
- 685 52. Reiff T, Eckstein HH, Mansmann U, et al. Angioplasty in asymptomatic carotid artery
686 stenosis vs. endarterectomy compared to best medical treatment: One-year interim results
687 of SPACE-2. *International journal of stroke : official journal of the International Stroke*
688 *Society* 2019; 15: 1747493019833017. 2019/03/16. DOI: 10.1177/1747493019833017.
- 689 53. Lee PH, Song JK, Kim JS, et al. Cryptogenic Stroke and High-Risk Patent Foramen Ovale:
690 The DEFENSE-PFO Trial. *Journal of the American College of Cardiology* 2018; 71: 2335-
691 2342. 2018/03/17. DOI: 10.1016/j.jacc.2018.02.046.
- 692 54. Saver JL, Mattle HP and Thaler D. Patent Foramen Ovale Closure Versus Medical Therapy
693 for Cryptogenic Ischemic Stroke: A Topical Review. *Stroke* 2018; 49: 1541-1548.
694 2018/05/16. DOI: 10.1161/strokeaha.117.018153.
- 695 55. Mas JL, Derex L, Guérin P, et al. Transcatheter closure of patent foramen ovale to prevent
696 stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert
697 consensus of the French Neurovascular Society and the French Society of Cardiology.
698 *Arch Cardiovasc Dis* 2019; 112: 532-542. 2019/08/06. DOI: 10.1016/j.acvd.2019.06.002.
- 699 56. Turc G, Calvet D, Guerin P, Sroussi M, Chatellier G and Mas JL. Closure,
700 Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen
701 Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New
702 Insights From the CLOSE Study. *Journal of the American Heart Association* 2018; 7
703 2018/06/19. DOI: 10.1161/jaha.117.008356.
- 704 57. Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in Patients with Heart Failure, Sinus
705 Rhythm, and Coronary Disease. *The New England journal of medicine* 2018 2018/08/28.
706 DOI: 10.1056/NEJMoa1808848.

- 707 58. Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients with heart
708 failure and sinus rhythm. *The New England journal of medicine* 2012; 366: 1859-1869.
709 2012/05/04. DOI: 10.1056/NEJMoa1202299.
- 710 59. Homma S, Thompson JL, Sanford AR, et al. Benefit of warfarin compared with aspirin in
711 patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized
712 controlled trial. *Circulation Heart failure* 2013; 6: 988-997. 2013/07/25. DOI:
713 10.1161/circheartfailure.113.000372.
- 714 60. Navi BB, Reiner AS, Kamel H, et al. Risk of Arterial Thromboembolism in
715 Patients With Cancer. *Journal of the American College of Cardiology* 2017; 70: 926-938.
716 2017/08/19. DOI: 10.1016/j.jacc.2017.06.047.
- 717 61. Jang HS, Choi J, Shin J, et al. The Long-Term Effect of Cancer on Incident Stroke: A
718 Nationwide Population-Based Cohort Study in Korea. *Front Neurol* 2019; 10: 52.
719 2019/02/26. DOI: 10.3389/fneur.2019.00052.
- 720 62. O'Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially
721 modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a
722 case-control study. *Lancet (London, England)* 2016; 388: 761-775. 2016/07/20. DOI:
723 10.1016/s0140-6736(16)30506-2.
- 724 63. Sharma M, Hart RG, Connolly SJ, et al. Stroke Outcomes in the Cardiovascular Outcomes
725 for People using Anticoagulation Strategies (COMPASS) Trial. *Circulation* 2019
726 2019/01/23. DOI: 10.1161/circulationaha.118.035864.
- 727 64. Rioux B, Touma L, Nehme A, Gore G, Keezer MR and Gioia LC. Frequency and
728 predictors of occult cancer in ischemic stroke: A systematic review and meta-analysis.
729 *International journal of stroke : official journal of the International Stroke Society* 2021;
730 16: 12-19. 2020/11/17. DOI: 10.1177/1747493020971104.
- 731 65. Smith EE, Mountain A, Hill MD, et al. Canadian Stroke Best Practice Guidance During the
732 COVID-19 Pandemic. *Can J Neurol Sci* 2020; 47: 474-478. 2020/07/14. DOI:
733 10.1017/cjn.2020.74.

- 734 66. Iodice F, Romoli M, Giometto B, et al. Stroke and digital technology: a wake-up call from
735 COVID-19 pandemic. *Neurol Sci* 2021; 42: 805-809. 2021/01/13. DOI: 10.1007/s10072-
736 020-04993-3.
- 737 67. Nogueira R, Abdalkader M, Qureshi MM, et al. EXPRESS: Global Impact of the COVID-
738 19 Pandemic on Stroke Hospitalizations and Mechanical Thrombectomy Volumes.
739 *International journal of stroke : official journal of the International Stroke Society* 2021:
740 1747493021991652. 2021/01/19. DOI: 10.1177/1747493021991652.
- 741 68. O'Neill ZR, Deptuck HM, Quong L, et al. Who says "no" to participating in stroke clinical
742 trials and why: an observational study from the Vancouver Stroke Program. *Trials* 2019;
743 20: 313. 2019/06/04. DOI: 10.1186/s13063-019-3434-0.
- 744